1
|
Edouard T, Picot MC, Bajanca F, Huguet H, Guitarte A, Langeois M, Chesneau B, Van Kien PK, Garrigue E, Dulac Y, Amedro P. Health-related quality of life in children and adolescents with Marfan syndrome or related disorders: a controlled cross-sectional study. Orphanet J Rare Dis 2024; 19:180. [PMID: 38685042 PMCID: PMC11059743 DOI: 10.1186/s13023-024-03191-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2023] [Accepted: 04/19/2024] [Indexed: 05/02/2024] Open
Abstract
BACKGROUND This cross-sectional controlled study aims to assess health-related quality of life (HRQoL) of children and adolescents with a molecular diagnosis of Marfan syndrome (MFS) or related disorders and to evaluate the factors associated with HRQoL in this population. Sixty-three children with MFS and 124 age- and sex-matched healthy children were recruited. HRQoL was assessed using the Pediatric Quality of Life Inventory (PedsQL™) generic questionnaire. The correlation between HRQoL scores and the different continuous parameters (age, body mass index, disease severity, systemic score, aortic sinus diameter, and aerobic physical capacity) was evaluated using Pearson's or Spearman's coefficient. A multiple linear regression analysis was performed on the two health summary self-reported PedsQL™ scores (physical and psychosocial) to identify the factors associated with HRQoL in the MFS group. RESULTS Except for emotional functioning, all other domains of HRQoL (psychosocial and physical health, social and school functions) were significantly lower in children with MFS compared to matched healthy children. In the MFS group, the physical health summary score was significantly lower in female than in male patients (self-report: absolute difference [95%CI] = -8.7 [-17.0; -0.47], P = 0.04; proxy-report: absolute difference [95%CI] = -8.6 [-17.3; 0.02], P = 0.05) and also negatively correlated with the systemic score (self-report: R = -0.24, P = 0.06; proxy-report: R = -0.29, P = 0.03) and with the height Z-score (proxy-report: R = -0.29, P = 0.03). There was no significant difference in the physical health summary scores between the different genetic subgroups. In the subgroup of 27 patients who performed a cardiopulmonary exercise test, self- and proxy-reported physical health summary scores were highly correlated with their aerobic physical capacity assessed by peak oxygen consumption (VO2max) and ventilatory anaerobic threshold (VAT). In the multivariate analysis, the most important independent predictors of decreased physical health were increased height, decreased body mass index, decreased VAT and use of prophylactic therapy. CONCLUSIONS This study reports an impaired HRQoL in children and adolescents with MFS or related conditions, in comparison with matched healthy children. Educational and rehabilitation programs must be developed and evaluated to improve exercise capacity and HRQoL in these patients. TRIAL REGISTRATION ClinicalTrials.gov, NCT03236571 . Registered 28 July 2017.
Collapse
Affiliation(s)
- Thomas Edouard
- Reference Center for Marfan Syndrome and Related Diseases, Children's Hospital, Toulouse University Hospital, RESTORE, INSERM U1301, Paul Sabatier University, Toulouse, France.
- Endocrine, Bone Diseases, and Genetics Unit, Children's Hospital, Toulouse University Hospital, 330 Avenue de Grande-Bretagne TSA 70034, Toulouse Cedex 9, 31059, France.
| | - Marie-Christine Picot
- Epidemiology and Clinical Research Department, Montpellier University Hospital, Montpellier, France
| | - Fernanda Bajanca
- Reference Center for Marfan Syndrome and Related Diseases, Children's Hospital, Toulouse University Hospital, RESTORE, INSERM U1301, Paul Sabatier University, Toulouse, France
| | - Helena Huguet
- Epidemiology and Clinical Research Department, Montpellier University Hospital, Montpellier, France
| | - Aitor Guitarte
- Reference Center for Marfan Syndrome and Related Diseases, Children's Hospital, Toulouse University Hospital, RESTORE, INSERM U1301, Paul Sabatier University, Toulouse, France
| | - Maud Langeois
- Reference Center for Marfan Syndrome and Related Diseases, Children's Hospital, Toulouse University Hospital, RESTORE, INSERM U1301, Paul Sabatier University, Toulouse, France
| | - Bertrand Chesneau
- Reference Center for Marfan Syndrome and Related Diseases, Children's Hospital, Toulouse University Hospital, RESTORE, INSERM U1301, Paul Sabatier University, Toulouse, France
| | | | - Eric Garrigue
- Reference Center for Marfan Syndrome and Related Diseases, Children's Hospital, Toulouse University Hospital, RESTORE, INSERM U1301, Paul Sabatier University, Toulouse, France
| | - Yves Dulac
- Reference Center for Marfan Syndrome and Related Diseases, Children's Hospital, Toulouse University Hospital, RESTORE, INSERM U1301, Paul Sabatier University, Toulouse, France
| | - Pascal Amedro
- Department of Pediatric and Adult Congenital Cardiology, M3C National Reference Centre, Bordeaux University Hospital, IHU Liryc, INSERM 1045, University of Bordeaux, Bordeaux, France
| |
Collapse
|
2
|
Faivre L, Crépin JC, Réda M, Nambot S, Carmignac V, Abadie C, Mirault T, Faure-Conter C, Mazereeuw-Hautier J, Maza A, Puzenat E, Collonge-Rame MA, Bursztejn AC, Philippe C, Thauvin-Robinet C, Chevarin M, Abasq-Thomas C, Amiel J, Arpin S, Barbarot S, Baujat G, Bessis D, Bourrat E, Boute O, Chassaing N, Coubes C, Demeer B, Edery P, El Chehadeh S, Goldenberg A, Hadj-Rabia S, Haye D, Isidor B, Jacquemont ML, Van Kien PK, Lacombe D, Lehalle D, Lambert L, Martin L, Maruani A, Morice-Picard F, Petit F, Phan A, Pinson L, Rossi M, Touraine R, Vanlerberghe C, Vincent M, Vincent-Delorme C, Whalen S, Willems M, Marle N, Verkarre V, Devalland C, Devouassoux-Shisheboran M, Abad M, Rioux-Leclercq N, Bonniaud B, Duffourd Y, Martel J, Binquet C, Kuentz P, Vabres P. Low risk of embryonic and other cancers in PIK3CA-related overgrowth spectrum: Impact on screening recommendations. Clin Genet 2023; 104:554-563. [PMID: 37580112 DOI: 10.1111/cge.14410] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2022] [Revised: 07/07/2023] [Accepted: 07/19/2023] [Indexed: 08/16/2023]
Abstract
The PIK3CA-related overgrowth spectrum (PROS) encompasses various conditions caused by mosaic activating PIK3CA variants. PIK3CA somatic variants are also involved in various cancer types. Some generalized overgrowth syndromes are associated with an increased risk of Wilms tumor (WT). In PROS, abdominal ultrasound surveillance has been advocated to detect WT. We aimed to determine the risk of embryonic and other types of tumors in patients with PROS in order to evaluate surveillance relevance. We searched the clinical charts from 267 PROS patients for the diagnosis of cancer, and reviewed the medical literature for the risk of cancer. In our cohort, six patients developed a cancer (2.2%), and Kaplan Meier analyses estimated cumulative probabilities of cancer occurrence at 45 years of age was 5.6% (95% CI = 1.35%-21.8%). The presence of the PIK3CA variant was only confirmed in two out of four tumor samples. In the literature and our cohort, six cases of Wilms tumor/nephrogenic rests (0.12%) and four cases of other cancers have been reported out of 483 proven PIK3CA patients, in particular the p.(His1047Leu/Arg) variant. The risk of WT in PROS being lower than 5%, this is insufficient evidence to recommend routine abdominal imaging. Long-term follow-up studies are needed to evaluate the risk of other cancer types, as well as the relationship with the extent of tissue mosaicism and the presence or not of the variant in the tumor samples.
Collapse
Affiliation(s)
- Laurence Faivre
- Equipe INSERM UMR1231, Génétique des Anomalies du Développement, FHU TRANSLAD, Université Bourgogne Franche-Comté, Dijon, France
- Centre de Génétique, Centre de Référence Anomalies du Développement et Syndromes Malformatifs et FHU TRANSLAD, CHU Dijon Bourgogne, Dijon, France
| | - Jean-Charles Crépin
- Equipe INSERM UMR1231, Génétique des Anomalies du Développement, FHU TRANSLAD, Université Bourgogne Franche-Comté, Dijon, France
- Service de Dermatologie, CHU Dijon Bourgogne, Dijon, France
- Centre de référence Maladies Rares Génétiques à Expression Cutanée (MAGEC), CHU Dijon, Dijon, France
| | - Manon Réda
- Oncogénétique, Centre de lutte contre le cancer Georges François Leclerc, Dijon, France
| | - Sophie Nambot
- Equipe INSERM UMR1231, Génétique des Anomalies du Développement, FHU TRANSLAD, Université Bourgogne Franche-Comté, Dijon, France
- Centre de Génétique, Centre de Référence Anomalies du Développement et Syndromes Malformatifs et FHU TRANSLAD, CHU Dijon Bourgogne, Dijon, France
- Oncogénétique, Centre de lutte contre le cancer Georges François Leclerc, Dijon, France
| | - Virginie Carmignac
- Equipe INSERM UMR1231, Génétique des Anomalies du Développement, FHU TRANSLAD, Université Bourgogne Franche-Comté, Dijon, France
- Centre de référence Maladies Rares Génétiques à Expression Cutanée (MAGEC), CHU Dijon, Dijon, France
| | | | - Tristan Mirault
- Université Paris Cité, PARCC INSERM U970, Centre de référence des maladies vasculaires rares, Hôpital européen Georges-Pompidou, Assistance Publique Hôpitaux de Paris, Paris, France
| | | | | | - Aude Maza
- Service de Dermatologie, CHU Toulouse, Toulouse, France
| | - Eve Puzenat
- Service de Dermatologie, CHU Besançon, Besançon, France
| | | | | | - Christophe Philippe
- Equipe INSERM UMR1231, Génétique des Anomalies du Développement, FHU TRANSLAD, Université Bourgogne Franche-Comté, Dijon, France
- UF6254 Innovation en Diagnostic Génomique des Maladies Rares, Plate-forme de Biologie Hospitalo-Universitaire, CHU Dijon-Bourgogne, Dijon, France
| | - Christel Thauvin-Robinet
- Equipe INSERM UMR1231, Génétique des Anomalies du Développement, FHU TRANSLAD, Université Bourgogne Franche-Comté, Dijon, France
- Centre de Référence Déficiences Intellectuelles de Causes Rares, CHU Dijon Bourgogne, Dijon, France
| | - Martin Chevarin
- Equipe INSERM UMR1231, Génétique des Anomalies du Développement, FHU TRANSLAD, Université Bourgogne Franche-Comté, Dijon, France
- UF6254 Innovation en Diagnostic Génomique des Maladies Rares, Plate-forme de Biologie Hospitalo-Universitaire, CHU Dijon-Bourgogne, Dijon, France
| | - Claire Abasq-Thomas
- Département de Pédiatrie et Génétique Médicale, CHU Brest Morvan, Brest, France
| | - Jeanne Amiel
- Service de Médecine Génomique des Maladies Rares et Centre de Référence Anomalies du Développement et Syndromes Malformatifs, Hôpital Necker-Enfants Malades, AP-HP, Paris, France
| | - Stéphanie Arpin
- Service de Génétique Clinique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs, CHRU de Tours, Tours, France
| | | | - Geneviève Baujat
- Service de Médecine Génomique des Maladies Rares et Centre de Référence Anomalies du Développement et Syndromes Malformatifs, Hôpital Necker-Enfants Malades, AP-HP, Paris, France
| | - Didier Bessis
- Département de Dermatologie, CHRU de Montpellier, Montpellier, France
| | - Emmanuelle Bourrat
- Service de dermatologie, centre de référence maladies génétiques à expression cutanée MAGEC, CHU St-Louis, Service de pédiatrie générale, CHU Robert Debré, Paris, France
| | - Odile Boute
- Service de Génétique Clinique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs, CHU Lille, Lille, France
| | - Nicolas Chassaing
- Service de Génétique Médicale et Centre de Compétence Anomalies du Développement et Syndromes Malformatifs, CHU Toulouse, Toulouse, France
| | - Christine Coubes
- Département de Génétique Médicale, Maladies rares et Médecine Personnalisée, et Centre de Référence Anomalies du Développement et Syndromes Malformatifs, CHRU de Montpellier, Montpellier, France
| | - Bénédicte Demeer
- Centre d'Activité de Génétique Clinique et Oncogénétique, CHU d'Amiens, Amiens, France
| | - Patrick Edery
- Service de génétique, Centre de Référence Anomalies du Développement, Hospices Civils de Lyon, Bron, France
- INSERM U1028, CNRS UMR5292, Centre de Recherche en Neurosciences de Lyon, GENDEV Team, Université Claude Bernard Lyon 1, Bron, France
| | - Salima El Chehadeh
- Service de Génétique Médicale, Centre de Référence Déficiences Intellectuelles de Causes Rares, Institut de Génétique Médicale d'Alsace (IGMA), CHRU de Strasbourg, Strasbourg, France
| | - Alice Goldenberg
- Service de Génétique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs, CHU de Rouen et Centre Normand de Génomique Médicale et Médecine Personnalisée, Rouen, France
| | - Smail Hadj-Rabia
- Service de Dermatologie et Centre de Référence des Maladies Rares Génétiques à Expression Cutanée (MAGEC), Université Paris Descartes-Sorbonne Paris Cité, Institut Imagine, Hôpital Universitaire Necker Enfants Malades, Paris, France
| | - Damien Haye
- Service de Génétique Clinique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs, CHRU de Tours, Tours, France
| | - Bertrand Isidor
- Service de Génétique Médicale et Centre de Référence Anomalies du Développement et Syndromes Malformatifs, CHU de Nantes, Nantes, France
| | - Marie-Line Jacquemont
- Unité de Génétique Médicale et Centre de Référence Anomalies du Développement et Syndromes Malformatifs, CHU de la Réunion, Saint-Pierre, France
| | - Philippe Khau Van Kien
- Unité de Génétique Médicale et Cytogénétique, Centre de Compétence Anomalies du Développement et Syndromes Malformatifs, CHU de Nîmes, Nîmes, France
| | - Didier Lacombe
- Service de Génétique Médicale et Centre de Référence Anomalies du Développement et Syndromes Malformatifs, CHU de Bordeaux, Bordeaux, France
| | - Daphné Lehalle
- Equipe INSERM UMR1231, Génétique des Anomalies du Développement, FHU TRANSLAD, Université Bourgogne Franche-Comté, Dijon, France
| | - Laetitia Lambert
- Service de Génétique Clinique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs, CHU de Nancy, Nancy, France
| | | | | | - Fanny Morice-Picard
- Service de Génétique Clinique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs, CHU de Nancy, Nancy, France
- Service de Dermatologie, CHU de Bordeaux, Bordeaux, France
| | - Florence Petit
- Service de Génétique Clinique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs, CHU Lille, Lille, France
| | - Alice Phan
- Service de Dermatologie, CHU de Lyon, Lyon, France
| | - Lucile Pinson
- Département de Génétique Médicale, Maladies rares et Médecine Personnalisée, et Centre de Référence Anomalies du Développement et Syndromes Malformatifs, CHRU de Montpellier, Montpellier, France
| | - Massimiliano Rossi
- Service de génétique, Centre de Référence Anomalies du Développement, Hospices Civils de Lyon, Bron, France
- INSERM U1028, CNRS UMR5292, Centre de Recherche en Neurosciences de Lyon, GENDEV Team, Université Claude Bernard Lyon 1, Bron, France
| | - Renaud Touraine
- Service de Génétique Clinique et Centre de Compétence Anomalies du Développement et Syndromes Malformatifs, CHU de Saint-Etienne, Saint-Etienne, France
| | - Clémence Vanlerberghe
- Service de Génétique Clinique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs, CHU Lille, Lille, France
| | - Marie Vincent
- Service de Génétique Médicale et Centre de Référence Anomalies du Développement et Syndromes Malformatifs, CHU de Nantes, Nantes, France
| | - Catherine Vincent-Delorme
- Service de Génétique Clinique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs, CHU Lille, Lille, France
| | - Sandra Whalen
- Unité Fonctionnelle de Génétique Clinique, Hôpital Armand-Trousseau, Paris, France
| | - Marjolaine Willems
- Département de Génétique Médicale, Maladies rares et Médecine Personnalisée, et Centre de Référence Anomalies du Développement et Syndromes Malformatifs, CHRU de Montpellier, Montpellier, France
| | - Nathalie Marle
- UF6254 Innovation en Diagnostic Génomique des Maladies Rares, Plate-forme de Biologie Hospitalo-Universitaire, CHU Dijon-Bourgogne, Dijon, France
| | - Virginie Verkarre
- Service d'Anatomie Pathologique, Hôpital Européen Georges Pompidou, Paris, France et INSERM UMR 970, Equipe 13, PARCC Université de Paris Cité, Paris, France
| | - Christine Devalland
- Service d'Anatomie Pathologique, Hôpital Nord Franche Comté, Trevenans, France
| | | | - Marine Abad
- Service d'Anatomie Pathologique, CHU Besançon, Besançon, France
| | | | | | - Yannis Duffourd
- Equipe INSERM UMR1231, Génétique des Anomalies du Développement, FHU TRANSLAD, Université Bourgogne Franche-Comté, Dijon, France
| | - Jehanne Martel
- Centre de référence Maladies Rares Génétiques à Expression Cutanée (MAGEC), CHU Dijon, Dijon, France
| | - Christine Binquet
- INSERM, Université de Bourgogne, CHU Dijon Bourgogne, CIC 1432, Module Épidémiologie Clinique, Dijon, France
| | - Paul Kuentz
- Equipe INSERM UMR1231, Génétique des Anomalies du Développement, FHU TRANSLAD, Université Bourgogne Franche-Comté, Dijon, France
- Oncobiologie Génétique Bioinformatique, PCBio, CHU Besançon, Besançon, France
| | - Pierre Vabres
- Equipe INSERM UMR1231, Génétique des Anomalies du Développement, FHU TRANSLAD, Université Bourgogne Franche-Comté, Dijon, France
- Service de Dermatologie, CHU Dijon Bourgogne, Dijon, France
- Centre de référence Maladies Rares Génétiques à Expression Cutanée (MAGEC), CHU Dijon, Dijon, France
| |
Collapse
|
3
|
Celse T, Tingaud-Sequeira A, Dieterich K, Siegfried G, Lecaignec C, Bouneau L, Fannemel M, Salaun G, Laffargue F, Martinez G, Satre V, Vieville G, Bidart M, Soussi Zander C, Turesson AC, Splitt M, Reboul D, Chiesa J, Khau Van Kien P, Godin M, Gruchy N, Goel H, Palmer E, Demetriou K, Shalhoub C, Rooryck-Thambo C, Coutton C. OTX2 duplications: a recurrent cause of oculo-auriculo-vertebral spectrum. J Med Genet 2022; 60:620-626. [DOI: 10.1136/jmg-2022-108678] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2022] [Accepted: 10/14/2022] [Indexed: 11/13/2022]
Abstract
BackgroundOculo-auriculo-vertebral spectrum (OAVS) is the second most common cause of head and neck malformations in children after orofacial clefts. OAVS is clinically heterogeneous and characterised by a broad range of clinical features including ear anomalies with or without hearing loss, hemifacial microsomia, orofacial clefts, ocular defects and vertebral abnormalities. Various genetic causes were associated with OAVS and copy number variations represent a recurrent cause of OAVS, but the responsible gene often remains elusive.MethodsWe described an international cohort of 17 patients, including 10 probands and 7 affected relatives, presenting with OAVS and carrying a 14q22.3 microduplication detected using chromosomal microarray analysis. For each patient, clinical data were collected using a detailed questionnaire addressed to the referring clinicians. We subsequently studied the effects ofOTX2overexpression in a zebrafish model.ResultsWe defined a 272 kb minimal common region that only overlaps with theOTX2gene. Head and face defects with a predominance of ear malformations were present in 100% of patients. The variability in expressivity was significant, ranging from simple chondromas to severe microtia, even between intrafamilial cases. Heterologous overexpression ofOTX2in zebrafish embryos showed significant effects on early development with alterations in craniofacial development.ConclusionsOur results indicate that properOTX2dosage seems to be critical for the normal development of the first and second branchial arches. Overall, we demonstrated thatOTX2genomic duplications are a recurrent cause of OAVS marked by auricular malformations of variable severity.
Collapse
|
4
|
Lesieur-Sebellin M, Till M, Khau Van Kien P, Herve B, Bourgon N, Dupont C, Tabet AC, Barrois M, Coussement A, Loeuillet L, Mousty E, Ea V, El Assal A, Mary L, Jaillard S, Beneteau C, Le Vaillant C, Coutton C, Devillard F, Goumy C, Delabaere A, Redon S, Laurent Y, Lamouroux A, Massardier J, Turleau C, Sanlaville D, Cantagrel V, Sonigo P, Vialard F, Salomon LJ, Malan V. Terminal 6q deletions cause brain malformations, a phenotype mimicking heterozygous DLL1 pathogenic variants: A multicenter retrospective case series. Prenat Diagn 2021; 42:118-135. [PMID: 34894355 DOI: 10.1002/pd.6074] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2021] [Revised: 11/24/2021] [Accepted: 11/30/2021] [Indexed: 12/14/2022]
Abstract
OBJECTIVE Terminal 6q deletion is a rare genetic condition associated with a neurodevelopmental disorder characterized by intellectual disability and structural brain anomalies. Interestingly, a similar phenotype is observed in patients harboring pathogenic variants in the DLL1 gene. Our study aimed to further characterize the prenatal phenotype of this syndrome as well as to attempt to establish phenotype-genotype correlations. METHOD We collected ultrasound findings from 22 fetuses diagnosed with a pure 6qter deletion. We reviewed the literature and compared our 22 cases with 14 fetuses previously reported as well as with patients with heterozygous DLL1 pathogenic variants. RESULTS Brain structural alterations were observed in all fetuses. The most common findings (>70%) were cerebellar hypoplasia, ventriculomegaly, and corpus callosum abnormalities. Gyration abnormalities were observed in 46% of cases. Occasional findings included cerebral heterotopia, aqueductal stenosis, vertebral malformations, dysmorphic features, and kidney abnormalities. CONCLUSION This is the first series of fetuses diagnosed with pure terminal 6q deletion. Based on our findings, we emphasize the prenatal sonographic anomalies, which may suggest the syndrome. Furthermore, this study highlights the importance of chromosomal microarray analysis to search for submicroscopic deletions of the 6q27 region involving the DLL1 gene in fetuses with these malformations.
Collapse
Affiliation(s)
- Marion Lesieur-Sebellin
- Service de Médecine Génomique des Maladies Rares, APHP-Centre, Hôpital Necker-Enfants Malades, Paris, France
- Faculté de Médecine, Sorbonne Université, Paris, France
| | - Marianne Till
- Laboratoire de Cytogénétique, service de Génétique, Hospices Civils de Lyon, Groupement Hospitalier Est, Bron, France
| | | | - Bérénice Herve
- Département de Génétique, CHI Poissy Saint-Germain, Saint-Germain, France
- Université Paris-Saclay, UVSQ, INRAE, BREED, Jouy-en-Josas, France
| | - Nicolas Bourgon
- Service d'Obstétrique et de Médecine Fœtale, APHP-Centre, Hôpital Necker-Enfants Malades, Paris, France
| | - Céline Dupont
- Département de Génétique, Unité de Cytogénétique, Hôpital Robert Debré, APHP Nord, Paris, France
| | - Anne-Claude Tabet
- Département de Génétique, Unité de Cytogénétique, Hôpital Robert Debré, APHP Nord, Paris, France
- Génétique Humaine et Fonctions Cognitives, Institut Pasteur, UMR3571 CNRS, Université de Paris, Paris, France
| | - Mathilde Barrois
- Maternité Port Royal, APHP Centre, Hôpital Cochin, Paris, France
| | - Aurélie Coussement
- Service des Maladies Génétiques de système et d'organes, APHP-Centre, Hôpital Cochin, Paris, France
| | - Laurence Loeuillet
- Service de Médecine Génomique des Maladies Rares, APHP-Centre, Hôpital Necker-Enfants Malades, Paris, France
| | - Eve Mousty
- Service de Gynécologie Obstétrique, Hôpital Caremeau, Nîmes, France
| | - Vuthy Ea
- UF de Cytogénétique et Génétique Médicale, Hôpital Caremeau, Nîmes, France
| | - Amal El Assal
- Département de Gynécologie Obstétrique, CHI Poissy Saint-Germain, Saint-Germain, France
| | - Laura Mary
- Service d'Anatomie Pathologique, CHU Rennes, Rennes, France
- Service de Cytogénétique et Biologie Cellulaire, CHU Rennes, Rennes, France
| | - Sylvie Jaillard
- Service de Cytogénétique et Biologie Cellulaire, CHU Rennes, Rennes, France
- INSERM, EHESP, IRSET, Université Rennes 1, Rennes, France
| | - Claire Beneteau
- Service de Génétique Médicale, CHU Nantes, Nantes, France
- UF de Fœtopathologie et Génétique, CHU de Nantes, Nantes, France
| | | | - Charles Coutton
- Service de Génétique, Génomique et Procréation, Hôpital Couple Enfant, CHU Grenoble Alpes, Grenoble, France
- Université Grenoble Alpes, INSERM U1209, CNRS UMR 5309, Institut pour l'Avancée des Biosciences, Equipe Génétique, Epigénétique et Thérapies de l'infertilité, Grenoble, France
| | - Françoise Devillard
- Service de Génétique, Génomique et Procréation, Hôpital Couple Enfant, CHU Grenoble Alpes, Grenoble, France
| | - Carole Goumy
- Cytogénétique Médicale, CHU Clermont-Ferrand, CHU Estaing, Université Clermont Auvergne, INSERM, U1240 Imagerie Moléculaire et Stratégies Théranostiques, Clermont-Ferrand, France
| | | | - Sylvia Redon
- CHU Brest, Inserm, Université de Brest, Brest, France
| | - Yves Laurent
- Service de Gynécologie et Obstétrique, GHBS Lorient, Lorient, France
| | - Audrey Lamouroux
- Service de Génétique Clinique, CHU Montpellier, Université de Montpellier, Montpellier, France
- Service de Gynécologie Obstétrique, CHU Nîmes, Université de Montpellier, Nîmes, France
| | - Jérôme Massardier
- Service de Gynécologie et Obstétrique, Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, Bron, France
| | - Catherine Turleau
- Service de Médecine Génomique des Maladies Rares, APHP-Centre, Hôpital Necker-Enfants Malades, Paris, France
| | - Damien Sanlaville
- Laboratoire de Cytogénétique, service de Génétique, Hospices Civils de Lyon, Groupement Hospitalier Est, Bron, France
| | - Vincent Cantagrel
- Université de Paris, Institut Imagine, Laboratoire de génétique des troubles du neurodéveloppement, Paris, France
- Université de Paris, Paris, France
| | - Pascale Sonigo
- Service de Radiologie Pédiatrique, APHP-Centre, Hôpital Necker-Enfants Malades, Paris, France
| | - François Vialard
- Département de Génétique, CHI Poissy Saint-Germain, Saint-Germain, France
- Université Paris-Saclay, UVSQ, INRAE, BREED, Jouy-en-Josas, France
| | - Laurent J Salomon
- Service d'Obstétrique et de Médecine Fœtale, APHP-Centre, Hôpital Necker-Enfants Malades, Paris, France
- Université de Paris, Paris, France
| | - Valérie Malan
- Service de Médecine Génomique des Maladies Rares, APHP-Centre, Hôpital Necker-Enfants Malades, Paris, France
- Université de Paris, Institut Imagine, Laboratoire de génétique des troubles du neurodéveloppement, Paris, France
- Université de Paris, Paris, France
| |
Collapse
|
5
|
Chesneau B, Plancke A, Rolland G, Marcheix B, Dulac Y, Edouard T, Plaisancié J, Aubert-Mucca M, Julia S, Langeois M, Lavabre-Bertrand T, Khau Van Kien P. A +3 variant at a donor splice site leads to a skipping of the MYH11 exon 32, a recurrent RNA defect causing Heritable Thoracic Aortic Aneurysm and Dissection and/or Patent Ductus Arteriosus. Mol Genet Genomic Med 2021; 9:e1814. [PMID: 34672437 PMCID: PMC8606209 DOI: 10.1002/mgg3.1814] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2021] [Revised: 08/11/2021] [Accepted: 09/03/2021] [Indexed: 12/29/2022] Open
Abstract
Background Pathogenic variants in MYH11 are associated with either heritable thoracic aortic aneurysm and dissection (HTAAD), patent ductus arteriosus (PDA) syndrome, or megacystis‐microcolon‐intestinal hypoperistalsis syndrome (MMIHS). Methods and Results We report a family referred for molecular diagnosis with HTAAD/PDA phenotype in which we found a variant at a non‐conserved position of the 5’ donor splice site of intron 32 of MYH11 potentially altering splicing (NM_002474.3:c.4578+3A>C). Although its cosegregation with disease was observed, it remained of unknown significance. Later, aortic surgery in the proband gave us the opportunity to perform a transcript analysis. This showed a skipping of the exon 32, an RNA defect previously reported to be translated to an in‐frame loss of 71 amino acids and a dominant‐negative effect in the smooth muscle myosin rod. This RNA defect is also reported in 3 other HTAAD/PDA pedigrees. Conclusion This report confirms that among rare variants in MYH11, skipping of exon 32 is recurrent. This finding is of particular interest to establish complex genotype–phenotype correlations where some alleles are associated with autosomal dominant HTAAD/PDA, while others result in recessive or dominant visceral myopathies.
Collapse
Affiliation(s)
- Bertrand Chesneau
- UF de Génétique Médicale et Cytogénétique, Centre Hospitalier Régional Universitaire de Nîmes, Nîmes, France.,Centre de Référence du syndrome de Marfan et des syndromes apparentés, Hôpital des Enfants, CHU de Toulouse, Toulouse, France
| | - Aurélie Plancke
- UF de Génétique Médicale et Cytogénétique, Centre Hospitalier Régional Universitaire de Nîmes, Nîmes, France
| | - Guillaume Rolland
- UF de Génétique Médicale et Cytogénétique, Centre Hospitalier Régional Universitaire de Nîmes, Nîmes, France
| | - Bertrand Marcheix
- Département de Chirurgie Cardiaque, Hôpital Universitaire de Rangueil, Toulouse, France
| | - Yves Dulac
- Centre de Référence du syndrome de Marfan et des syndromes apparentés, Hôpital des Enfants, CHU de Toulouse, Toulouse, France
| | - Thomas Edouard
- Centre de Référence du syndrome de Marfan et des syndromes apparentés, Hôpital des Enfants, CHU de Toulouse, Toulouse, France
| | - Julie Plaisancié
- Service de Génétique Médicale, Hôpital Universitaire de Purpan, Toulouse, France
| | - Marion Aubert-Mucca
- Centre de Référence du syndrome de Marfan et des syndromes apparentés, Hôpital des Enfants, CHU de Toulouse, Toulouse, France.,Service de Génétique Médicale, Hôpital Universitaire de Purpan, Toulouse, France
| | - Sophie Julia
- Service de Génétique Médicale, Hôpital Universitaire de Purpan, Toulouse, France
| | - Maud Langeois
- Centre de Référence du syndrome de Marfan et des syndromes apparentés, Hôpital des Enfants, CHU de Toulouse, Toulouse, France.,Service de Génétique Médicale, Hôpital Universitaire de Purpan, Toulouse, France
| | - Thierry Lavabre-Bertrand
- UF de Génétique Médicale et Cytogénétique, Centre Hospitalier Régional Universitaire de Nîmes, Nîmes, France.,Institut des Biomolécules Max Mousseron (IBMM), CNRS UMR5247, Université de Montpellier, Montpellier, France.,Faculté de Médecine Montpellier-Nîmes, Laboratoire d'Histologie-Embryologie-Cytogénétique, Institut des Biomolécules Max Mousseron (IBMM), CNRS UMR5247, Nîmes, France
| | - Philippe Khau Van Kien
- UF de Génétique Médicale et Cytogénétique, Centre Hospitalier Régional Universitaire de Nîmes, Nîmes, France.,Institut des Biomolécules Max Mousseron (IBMM), CNRS UMR5247, Université de Montpellier, Montpellier, France.,Faculté de Médecine Montpellier-Nîmes, Laboratoire d'Histologie-Embryologie-Cytogénétique, Institut des Biomolécules Max Mousseron (IBMM), CNRS UMR5247, Nîmes, France
| |
Collapse
|
6
|
Chesneau B, Plancke A, Rolland G, Chassaing N, Coubes C, Brischoux-Boucher E, Edouard T, Dulac Y, Aubert-Mucca M, Lavabre-Bertrand T, Plaisancié J, Khau Van Kien P. Parental mosaicism in Marfan and Ehlers-Danlos syndromes and related disorders. Eur J Hum Genet 2021; 29:771-779. [PMID: 33414558 PMCID: PMC8110803 DOI: 10.1038/s41431-020-00797-3] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2020] [Revised: 11/25/2020] [Accepted: 12/02/2020] [Indexed: 01/29/2023] Open
Abstract
Marfan syndrome (MFS) is a heritable connective tissue disorder (HCTD) caused by pathogenic variants in FBN1 that frequently occur de novo. Although individuals with somatogonadal mosaicisms have been reported with respect to MFS and other HCTD, the overall frequency of parental mosaicism in this pathology is unknown. In an attempt to estimate this frequency, we reviewed all the 333 patients with a disease-causing variant in FBN1. We then used direct sequencing, combined with High Resolution Melting Analysis, to detect mosaicism in their parents, complemented by NGS when a mosaicism was objectivized. We found that (1) the number of apparently de novo events is much higher than the classically admitted number (around 50% of patients and not 25% as expected for FBN1) and (2) around 5% of the FBN1 disease-causing variants were not actually de novo as anticipated, but inherited in a context of somatogonadal mosaicisms revealed in parents from three families. High Resolution Melting Analysis and NGS were more efficient at detecting and evaluating the level of mosaicism compared to direct Sanger sequencing. We also investigated individuals with a causal variant in another gene identified through our "aortic diseases genes" NGS panel and report, for the first time, on an individual with a somatogonadal mosaicism in COL5A1. Our study shows that parental mosaicism is not that rare in Marfan syndrome and should be investigated with appropriate methods given its implications in patient's management.
Collapse
Affiliation(s)
- Bertrand Chesneau
- UF de Génétique Médicale et Cytogénétique, Centre Hospitalier Universitaire de Nîmes, Nîmes, France ,Centre de Référence du Syndrome de Marfan et des Syndromes Apparentés, Hôpital des Enfants, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - Aurélie Plancke
- UF de Génétique Médicale et Cytogénétique, Centre Hospitalier Universitaire de Nîmes, Nîmes, France
| | - Guillaume Rolland
- UF de Génétique Médicale et Cytogénétique, Centre Hospitalier Universitaire de Nîmes, Nîmes, France
| | - Nicolas Chassaing
- Service de Génétique Médicale, Hôpital Purpan, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - Christine Coubes
- Service de Génétique Clinique, Département de Génétique Médicale, Maladies Rares et Médecine Personnalisée, Hôpital Arnaud de Villeneuve, Centre Hospitalier Universitaire de Montpellier, Montpellier, France
| | | | - Thomas Edouard
- Centre de Référence du Syndrome de Marfan et des Syndromes Apparentés, Hôpital des Enfants, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - Yves Dulac
- Centre de Référence du Syndrome de Marfan et des Syndromes Apparentés, Hôpital des Enfants, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - Marion Aubert-Mucca
- Centre de Référence du Syndrome de Marfan et des Syndromes Apparentés, Hôpital des Enfants, Centre Hospitalier Universitaire de Toulouse, Toulouse, France ,Service de Génétique Médicale, Hôpital Purpan, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - Thierry Lavabre-Bertrand
- UF de Génétique Médicale et Cytogénétique, Centre Hospitalier Universitaire de Nîmes, Nîmes, France
| | - Julie Plaisancié
- Centre de Référence du Syndrome de Marfan et des Syndromes Apparentés, Hôpital des Enfants, Centre Hospitalier Universitaire de Toulouse, Toulouse, France ,Service de Génétique Médicale, Hôpital Purpan, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - Philippe Khau Van Kien
- UF de Génétique Médicale et Cytogénétique, Centre Hospitalier Universitaire de Nîmes, Nîmes, France
| |
Collapse
|
7
|
Garde A, Guibaud L, Goldenberg A, Petit F, Dard R, Roume J, Mazereeuw-Hautier J, Chassaing N, Lacombe D, Morice-Picard F, Toutain A, Arpin S, Boccara O, Touraine R, Blanchet P, Coubes C, Willems M, Pinson L, Van Kien PK, Chiaverini C, Giuliano F, Alessandri JL, Mathieu-Dramard M, Morin G, Bursztejn AC, Mignot C, Doummar D, Di Rocco F, Cornaton J, Nicolas C, Gautier E, Luu M, Bardou M, Sorlin A, Philippe C, Edery P, Rossi M, Carmignac V, Thauvin-Robinet C, Vabres P, Faivre L. Clinical and neuroimaging findings in 33 patients with MCAP syndrome: A survey to evaluate relevant endpoints for future clinical trials. Clin Genet 2021; 99:650-661. [PMID: 33415748 DOI: 10.1111/cge.13918] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2020] [Revised: 12/17/2020] [Accepted: 01/04/2021] [Indexed: 11/30/2022]
Abstract
Megalencephaly-CApillary malformation-Polymicrogyria (MCAP) syndrome results from somatic mosaic gain-of-function variants in PIK3CA. Main features are macrocephaly, somatic overgrowth, cutaneous vascular malformations, connective tissue dysplasia, neurodevelopmental delay, and brain anomalies. The objectives of this study were to describe the clinical and radiological features of MCAP, to suggest relevant clinical endpoints applicable in future trials of targeted drug therapy. Based on a French collaboration, we collected clinical features of 33 patients (21 females, 12 males, median age of 9.9 years) with MCAP carrying mosaic PIK3CA pathogenic variants. MRI images were reviewed for 21 patients. The main clinical features reported were macrocephaly at birth (20/31), postnatal macrocephaly (31/32), body/facial asymmetry (21/33), cutaneous capillary malformations (naevus flammeus 28/33, cutis marmorata 17/33). Intellectual disability was present in 15 patients. Among the MRI images reviewed, the neuroimaging findings were megalencephaly (20/21), thickening of corpus callosum (16/21), Chiari malformation (12/21), ventriculomegaly/hydrocephaly (10/21), cerebral asymmetry (6/21) and polymicrogyria (2/21). This study confirms the main known clinical features that defines MCAP syndrome. Taking into account the phenotypic heterogeneity in MCAP patients, in the context of emerging clinical trials, we suggest that patients should be evaluated based on the main neurocognitive expression on each patient.
Collapse
Affiliation(s)
- Aurore Garde
- Centre de Référence Anomalies du Développement et Syndromes Malformatifs, FHU TRANSLAD, Hôpital d'Enfants, CHU Dijon, Dijon, France.,Unité Fonctionnelle Innovation en Diagnostic génomique des maladies rares, FHU-TRANSLAD, CHU Dijon Bourgogne, Dijon, France
| | - Laurent Guibaud
- Service de Radiologie, Hôpital Femme-Mère-Enfant, Lyon, France
| | | | - Florence Petit
- Service de Génétique Clinique, Centre de Référence Anomalies du Développement CHU, Lille, France
| | - Rodolphe Dard
- Département de Génétique, CHI Poissy, St Germain-en-Laye, France
| | - Joelle Roume
- Département de Génétique, CHI Poissy, St Germain-en-Laye, France
| | - Juliette Mazereeuw-Hautier
- Département de Dermatologie, Centre de Référence des Maladies Rares de la Peau, CHU de Toulouse, Toulouse, France
| | - Nicolas Chassaing
- Service de Génétique Médicale, INSERM U543, Hôpital Purpan, CHU de Toulouse, Toulouse, France
| | - Didier Lacombe
- INSERM U1211, Service de Génétique Médicale, CHU de Bordeaux, Bordeaux, France
| | - Fanny Morice-Picard
- INSERM U1211, Service de Génétique Médicale, CHU de Bordeaux, Bordeaux, France
| | | | | | - Olivia Boccara
- Département de Dermatologie, Centre de Reference MAGEC, Hopital universitaire Necker-Enfants malades, Paris, France
| | - Renaud Touraine
- Service de Génétique Clinique, Chromosomique et Moléculaire, Centre de Référence des Anomalies du Développement, CHU, de Saint-Etienne, France
| | - Patricia Blanchet
- Département de Génétique Médicale, Maladies rares et Médecine Personnalisée, CHRU de Montpellier, Montpellier, France
| | - Christine Coubes
- Département de Génétique Médicale, Maladies rares et Médecine Personnalisée, CHRU de Montpellier, Montpellier, France
| | - Marjolaine Willems
- Département de Génétique Médicale, Maladies rares et Médecine Personnalisée, CHRU de Montpellier, Montpellier, France
| | - Lucile Pinson
- Département de Génétique Médicale, Maladies rares et Médecine Personnalisée, CHRU de Montpellier, Montpellier, France
| | | | | | | | | | | | - Gilles Morin
- Service de Génétique Clinique, CHU Amiens-Picardie, Amiens, France
| | | | - Cyril Mignot
- Département de Génétique and Centre de Référence Déficiences Intellectuelles de Causes Rares, AP-HP, Sorbonne Université, Paris, France
| | - Diane Doummar
- Service de Neurologie pédiatrique, Hôpital Armand Trousseau, AP-HP, Paris, France
| | - Frederico Di Rocco
- Service de neurochirurgie pédiatrique, Hôpital Femme-Mère-Enfant, Lyon, France
| | - Jenny Cornaton
- Centre de Référence Anomalies du Développement et Syndromes Malformatifs, FHU TRANSLAD, Hôpital d'Enfants, CHU Dijon, Dijon, France
| | - Claire Nicolas
- Centre de Référence Anomalies du Développement et Syndromes Malformatifs, FHU TRANSLAD, Hôpital d'Enfants, CHU Dijon, Dijon, France
| | - Elodie Gautier
- Centre de Référence Anomalies du Développement et Syndromes Malformatifs, FHU TRANSLAD, Hôpital d'Enfants, CHU Dijon, Dijon, France
| | - Maxime Luu
- INSERM CIC 1432, Université de Bourgogne, Dijon, France
| | - Marc Bardou
- INSERM CIC 1432, Université de Bourgogne, Dijon, France
| | - Arthur Sorlin
- Centre de Référence Anomalies du Développement et Syndromes Malformatifs, FHU TRANSLAD, Hôpital d'Enfants, CHU Dijon, Dijon, France.,Unité Fonctionnelle Innovation en Diagnostic génomique des maladies rares, FHU-TRANSLAD, CHU Dijon Bourgogne, Dijon, France.,UMR1231 GAD, Inserm - Université Bourgogne-Franche Comté, Dijon, France
| | - Christophe Philippe
- Unité Fonctionnelle Innovation en Diagnostic génomique des maladies rares, FHU-TRANSLAD, CHU Dijon Bourgogne, Dijon, France.,UMR1231 GAD, Inserm - Université Bourgogne-Franche Comté, Dijon, France
| | - Patrick Edery
- Département de Génétique, Hospices Civils de Lyon et GENDEV, INSERM U1028, Lyon, France
| | - Massimiliano Rossi
- Département de Génétique, Hospices Civils de Lyon et GENDEV, INSERM U1028, Lyon, France
| | - Virginie Carmignac
- UMR1231 GAD, Inserm - Université Bourgogne-Franche Comté, Dijon, France.,Centre de Référence MAGEC, Service de Dermatologie, Centre Hospitalier Universitaire Dijon Bourgogne, Dijon, France
| | - Christel Thauvin-Robinet
- Centre de Référence Anomalies du Développement et Syndromes Malformatifs, FHU TRANSLAD, Hôpital d'Enfants, CHU Dijon, Dijon, France.,Unité Fonctionnelle Innovation en Diagnostic génomique des maladies rares, FHU-TRANSLAD, CHU Dijon Bourgogne, Dijon, France.,UMR1231 GAD, Inserm - Université Bourgogne-Franche Comté, Dijon, France
| | - Pierre Vabres
- UMR1231 GAD, Inserm - Université Bourgogne-Franche Comté, Dijon, France.,Centre de Référence MAGEC, Service de Dermatologie, Centre Hospitalier Universitaire Dijon Bourgogne, Dijon, France
| | - Laurence Faivre
- Centre de Référence Anomalies du Développement et Syndromes Malformatifs, FHU TRANSLAD, Hôpital d'Enfants, CHU Dijon, Dijon, France.,Unité Fonctionnelle Innovation en Diagnostic génomique des maladies rares, FHU-TRANSLAD, CHU Dijon Bourgogne, Dijon, France.,Centre de Référence MAGEC, Service de Dermatologie, Centre Hospitalier Universitaire Dijon Bourgogne, Dijon, France
| |
Collapse
|
8
|
Liu H, Giguet-Valard AG, Simonet T, Szenker-Ravi E, Lambert L, Vincent-Delorme C, Scheidecker S, Fradin M, Morice-Picard F, Naudion S, Ciorna-Monferrato V, Colin E, Fellmann F, Blesson S, Jouk PS, Francannet C, Petit F, Moutton S, Lehalle D, Chassaing N, El Zein L, Bazin A, Bénéteau C, Attié-Bitach T, Hanu SM, Brechard MP, Chiesa J, Pasquier L, Rooryck-Thambo C, Van Maldergem L, Cabrol C, El Chehadeh S, Vasiljevic A, Isidor B, Abel C, Thevenon J, Di Filippo S, Vigouroux-Castera A, Attia J, Quelin C, Odent S, Piard J, Giuliano F, Putoux A, Khau Van Kien P, Yardin C, Touraine R, Reversade B, Bouvagnet P. Next-generation sequencing in a series of 80 fetuses with complex cardiac malformations and/or heterotaxy. Hum Mutat 2020; 41:2167-2178. [PMID: 33131162 DOI: 10.1002/humu.24132] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2020] [Revised: 09/21/2020] [Accepted: 10/02/2020] [Indexed: 11/07/2022]
Abstract
Herein, we report the screening of a large panel of genes in a series of 80 fetuses with congenital heart defects (CHDs) and/or heterotaxy and no cytogenetic anomalies. There were 49 males (61%/39%), with a family history in 28 cases (35%) and no parental consanguinity in 77 cases (96%). All fetuses had complex CHD except one who had heterotaxy and midline anomalies while 52 cases (65%) had heterotaxy in addition to CHD. Altogether, 29 cases (36%) had extracardiac and extra-heterotaxy anomalies. A pathogenic variant was found in 10/80 (12.5%) cases with a higher percentage in the heterotaxy group (8/52 cases, 15%) compared with the non-heterotaxy group (2/28 cases, 7%), and in 3 cases with extracardiac and extra-heterotaxy anomalies (3/29, 10%). The inheritance was recessive in six genes (DNAI1, GDF1, MMP21, MYH6, NEK8, and ZIC3) and dominant in two genes (SHH and TAB2). A homozygous pathogenic variant was found in three cases including only one case with known consanguinity. In conclusion, after removing fetuses with cytogenetic anomalies, next-generation sequencing discovered a causal variant in 12.5% of fetal cases with CHD and/or heterotaxy. Genetic counseling for future pregnancies was greatly improved. Surprisingly, unexpected consanguinity accounts for 20% of cases with identified pathogenic variants.
Collapse
Affiliation(s)
- Hui Liu
- Department of Anatomy, Hainan Medical College, Haikou, Hainan, China
| | | | - Thomas Simonet
- Centre de Biotechnologie Cellulaire, Groupe Hospitalier Est, CHU Lyon, Lyon, Bron, France
| | - Emmanuelle Szenker-Ravi
- Human Genetics & Embryology Laboratory, Institute of Medical Biology, A*STAR, Singapore, Singapore
| | - Laetitia Lambert
- Génétique Clinique UF6211, CHU Nancy, Maternité Régionale Universitaire, Nancy, France
| | | | - Sophie Scheidecker
- Service de Génétique Médicale, Hôpital de Hautepierre, CHU Strasbourg, Strasbourg, France
| | - Mélanie Fradin
- Service de Génétique Médicale, CHU Rennes, Rennes, France
| | - Fanny Morice-Picard
- Service de Génétique Médicale, Hôpital Pellegrin, CHU Bordeaux, Bordeaux, France
| | - Sophie Naudion
- Service de Génétique Médicale, Hôpital Pellegrin, CHU Bordeaux, Bordeaux, France
| | | | - Estelle Colin
- Département de Biochimie et Génétique, CHU Angers, Angers, France
| | | | - Sophie Blesson
- Service de Génétique, Centre Hospitalier Bretonneau, CHU Tours, Tours, France
| | - Pierre-Simon Jouk
- Département de Génétique et Reproduction, CHU Grenoble Alpes, Grenoble, France
| | - Christine Francannet
- Service de Génétique Médicale, Hôpital Estaing, CHU Clermont-Ferrand, Clermont-Ferrand, France
| | - Florence Petit
- Clinique de Génétique Guy Fontaine, Hôpital Jeanne de Flandres, CHU Lille, Lille, France
| | | | - Daphné Lehalle
- Département de Génétique Médicale, CHU Dijon, Dijon, France
| | - Nicolas Chassaing
- Service de Génétique Médicale, Hôpital Purpan, CHU Toulouse, Toulouse, France
| | - Loubna El Zein
- Biology Department, Lebanese University, Beirut, Lebanon
| | - Anne Bazin
- Centre de Diagnostic Prénatal, CH Pontoise, Cergy Pontoise, France
| | | | - Tania Attié-Bitach
- Département de Génétique et Institut Imagine, Hôpital Necker-Enfants Malades, Paris, France
| | - Sylvie M Hanu
- Clinique de Génétique Guy Fontaine, Hôpital Jeanne de Flandres, CHU Lille, Lille, France
| | | | - Jean Chiesa
- Unité de Génétique Médicale et Cytogénétique, Hôpital Caremeau, CHU Nîmes, Nîmes, France
| | | | | | | | | | - Salima El Chehadeh
- Service de Génétique Médicale, Hôpital de Hautepierre, CHU Strasbourg, Strasbourg, France
| | - Alexandre Vasiljevic
- Laboratoire d'Anatomo-pathologie, Groupe Hospitalier Est, CHU Lyon, Lyon, France
| | | | - Carine Abel
- Centre de Diagnostic Prénatal, Hôpital de la Croix-Rousse, CHU Lyon, Lyon, France
| | - Julien Thevenon
- Département de Génétique et Reproduction, CHU Grenoble Alpes, Grenoble, France
| | - Sylvie Di Filippo
- Service de Cardiologie Pédiatrique, Groupe Hospitalier Est, CHU Lyon, Lyon, France
| | | | - Jocelyne Attia
- Centre de Diagnostic Prénatal, Centre Hospitalier Lyon Sud, Lyon, France
| | - Chloé Quelin
- Service de Génétique Médicale, CHU Rennes, Rennes, France
| | - Sylvie Odent
- Service de Génétique Médicale, CHU Rennes, Rennes, France
| | - Juliette Piard
- Centre de Génétique Humaine, CHU Franche-Comté, Besançon, France
| | - Fabienne Giuliano
- Service de Génétique Médicale, Hôpital de l'Archet 2, CHU Nice, Nice, France
| | - Audrey Putoux
- Service de Génétique Clinique, Groupe Hospitalier Est, CHU Lyon, Lyon, France
| | - Philippe Khau Van Kien
- Unité de Génétique Médicale et Cytogénétique, Hôpital Caremeau, CHU Nîmes, Nîmes, France
| | - Catherine Yardin
- Service de Cytogénétique, Génétique Médicale et Biologie de la Reproduction, Hôpital de la Mère et de l'Enfant, CHU Dupuytren, Limoges, France
| | - Renaud Touraine
- Service de Génétique, Hôpital Nord, CHU Saint Etienne, Saint Etienne, France
| | - Bruno Reversade
- Human Genetics & Embryology Laboratory, Institute of Medical Biology, A*STAR, Singapore, Singapore
| | - Patrice Bouvagnet
- Centre de Diagnostic Prénatal, Hôpital MFME, Fort de France, Martinique, France
| |
Collapse
|
9
|
Mary L, Chennen K, Stoetzel C, Antin M, Leuvrey A, Nourisson E, Alanio-Detton E, Antal MC, Attié-Bitach T, Bouvagnet P, Bouvier R, Buenerd A, Clémenson A, Devisme L, Gasser B, Gilbert-Dussardier B, Guimiot F, Khau Van Kien P, Leroy B, Loget P, Martinovic J, Pelluard F, Perez MJ, Petit F, Pinson L, Rooryck-Thambo C, Poch O, Dollfus H, Schaefer E, Muller J. Bardet-Biedl syndrome: Antenatal presentation of forty-five fetuses with biallelic pathogenic variants in known Bardet-Biedl syndrome genes. Clin Genet 2020; 95:384-397. [PMID: 30614526 DOI: 10.1111/cge.13500] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2018] [Revised: 12/20/2018] [Accepted: 12/29/2018] [Indexed: 02/06/2023]
Abstract
Bardet-Biedl syndrome (BBS) is an emblematic ciliopathy associated with retinal dystrophy, obesity, postaxial polydactyly, learning disabilities, hypogonadism and renal dysfunction. Before birth, enlarged/cystic kidneys as well as polydactyly are the hallmark signs of BBS to consider in absence of familial history. However, these findings are not specific to BBS, raising the problem of differential diagnoses and prognosis. Molecular diagnosis during pregnancies remains a timely challenge for this heterogeneous disease (22 known genes). We report here the largest cohort of BBS fetuses to better characterize the antenatal presentation. Prenatal ultrasound (US) and/or autopsy data from 74 fetuses with putative BBS diagnosis were collected out of which molecular diagnosis was established in 51 cases, mainly in BBS genes (45 cases) following the classical gene distribution, but also in other ciliopathy genes (6 cases). Based on this, an updated diagnostic decision tree is proposed. No genotype/phenotype correlation could be established but postaxial polydactyly (82%) and renal cysts (78%) were the most prevalent symptoms. However, autopsy revealed polydactyly that was missed by prenatal US in 55% of the cases. Polydactyly must be carefully looked for in pregnancies with apparently isolated renal anomalies in fetuses.
Collapse
Affiliation(s)
- Laura Mary
- Laboratoire de Diagnostic Génétique, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.,Laboratoire de Génétique Médicale, UMR_S INSERM U1112, IGMA, Faculté de Médecine FMTS, Université de Strasbourg, Strasbourg, France
| | - Kirsley Chennen
- Laboratoire de Génétique Médicale, UMR_S INSERM U1112, IGMA, Faculté de Médecine FMTS, Université de Strasbourg, Strasbourg, France.,Complex Systems and Translational Bioinformatics, ICube, University of Strasbourg, CNRS, Illkirch, France
| | - Corinne Stoetzel
- Laboratoire de Génétique Médicale, UMR_S INSERM U1112, IGMA, Faculté de Médecine FMTS, Université de Strasbourg, Strasbourg, France
| | - Manuela Antin
- Laboratoire de Diagnostic Génétique, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - Anne Leuvrey
- Laboratoire de Diagnostic Génétique, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - Elsa Nourisson
- Laboratoire de Diagnostic Génétique, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - Elisabeth Alanio-Detton
- Gynécologie-obstétrique, Centre de Dépistage Anténatal, Hôpital Maison-Blanche, Reims, France
| | - Maria C Antal
- Institut d'Histologie, Icube, Université de Strasbourg, Strasbourg, France.,Service de Pathologie, UF6349 Fœtopathologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - Tania Attié-Bitach
- INSERM U1163, Institut IMAGINE, Université Paris Descartes, Paris, France.,Service d'Histologie-Embryologie-Cytogénétique, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Patrice Bouvagnet
- Laboratoire de Cardiogénétique, Malformations Cardiaques Congénitale, Hôpitaux Civils de Lyon, France
| | - Raymonde Bouvier
- Département de Pathologie, Centre Hospitalier Est, Hôpitaux Civils de Lyon, Lyon, France
| | - Annie Buenerd
- Département de Pathologie, Centre Hospitalier Est, Hôpitaux Civils de Lyon, Lyon, France
| | - Alix Clémenson
- Service d'Anatomie et Cytologie Pathologiques, CHU de Saint-Etienne, Saint-Étienne, France
| | - Louise Devisme
- Institut d'Anatomo-Pathologie, Centre de Biologie Pathologie, Centre Hospitalier Universitaire de Lille, Lille, France
| | - Bernard Gasser
- Laboratoire de Pathologie, GHR Mulhouse-Sud Alsace, Mulhouse, France
| | - Brigitte Gilbert-Dussardier
- Service de Génétique Médicale, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.,EA3808 - NEUVACOD, Université de Poitiers, Poitiers, France
| | - Fabien Guimiot
- Unité Fonctionnelle de Fœtopathologie, Département de Génétique, Hôpital Robert Debré, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Philippe Khau Van Kien
- Unité de Génétique Médicale et Cytogénétique, Centre Hospitalier Universitaire de Nîmes, Nîmes, France
| | - Brigitte Leroy
- Service d'Anatomie Pathologique, CHI Poissy Saint Germain-en-Laye, Poissy, France
| | - Philippe Loget
- Service d'Anatomie Pathologique, Hôpital Pontchaillou, Université Rennes 1, Rennes, France
| | - Jelena Martinovic
- Unité de Fœtopathologie, Hôpital Antoine Béclère, Assistance Publique-Hôpitaux de Paris, Clamart, France
| | - Fanny Pelluard
- Service d'Anatomie-Cytologie Pathologique, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.,INSERM UMR1053, Bordeaux Research in Translational Oncology, BaRITOn, Université de Bordeaux, Bordeaux, France
| | - Marie-Josée Perez
- Unité de Fœtopathologie, Service de Génétique Médicale, Centre Hospitalier Universitaire, Montpellier, France
| | - Florence Petit
- Clinique de Génétique Guy Fontaine, Centre Hospitalier Universitaire de Lille, Lille, France
| | - Lucile Pinson
- Département de Génétique Médicale, Centre Hospitalier Régional Universitaire de Montpellier, Montpellier, France
| | - Caroline Rooryck-Thambo
- Université Bordeaux, MRGM INSERM U1211, CHU de Bordeaux, Service de Génétique Médicale, Bordeaux, France
| | - Olivier Poch
- Complex Systems and Translational Bioinformatics, ICube, University of Strasbourg, CNRS, Illkirch, France
| | - Hélène Dollfus
- Laboratoire de Génétique Médicale, UMR_S INSERM U1112, IGMA, Faculté de Médecine FMTS, Université de Strasbourg, Strasbourg, France.,Service de Génétique Médicale, IGMA, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.,Centre des Affections Rares en Génétique Ophtalmologique, FSMR SENSGENE, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - Elise Schaefer
- Laboratoire de Génétique Médicale, UMR_S INSERM U1112, IGMA, Faculté de Médecine FMTS, Université de Strasbourg, Strasbourg, France.,Service de Génétique Médicale, IGMA, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - Jean Muller
- Laboratoire de Diagnostic Génétique, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.,Laboratoire de Génétique Médicale, UMR_S INSERM U1112, IGMA, Faculté de Médecine FMTS, Université de Strasbourg, Strasbourg, France
| |
Collapse
|
10
|
Chesneau B, Edouard T, Dulac Y, Colineaux H, Langeois M, Hanna N, Boileau C, Arnaud P, Chassaing N, Julia S, Jondeau G, Plancke A, Khau Van Kien P, Plaisancié J. Clinical and genetic data of 22 new patients with SMAD3 pathogenic variants and review of the literature. Mol Genet Genomic Med 2020; 8:e1132. [PMID: 32154675 PMCID: PMC7216810 DOI: 10.1002/mgg3.1132] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2019] [Accepted: 01/07/2020] [Indexed: 12/23/2022] Open
Abstract
Background Pathogenic SMAD3 variants are responsible for a cardiovascular phenotype, mainly thoracic aortic aneurysms and dissections. Precocious identification of the vascular risk such as aortic dilatation in mutated patients has a major impact in terms of management, particularly to avoid dissection and sudden death. These vascular damages are classically associated with premature osteoarthritis and skeletal abnormalities. However, variable expressivity and incomplete penetrance are common with SMAD3 variants. Methods To investigate the clinical variability observed within SMAD3 patients, we reviewed the phenotypic and genetic data of 22 new patients from our Centre and of 133 patients reported in the literature. From this cohort of 155 mutated individuals, we first aimed to delineate an estimated frequency of the main clinical signs associated with SMAD3 pathogenic variants and, then, to look for genotype‐phenotype correlations, mainly to see if the aortic phenotype (AP) could be predicted by the SMAD3 variant type. Results We showed, herein, the absence of correlation between the SMAD3 variant type and the occurrence of an AP in patients. Conclusion Therefore, this report brings additional data for the genotype‐phenotype correlations of SMAD3 variants and the need to explore in more detail the effects of genetic modifiers that could influence the phenotype.
Collapse
Affiliation(s)
- Bertrand Chesneau
- Service de génétique médicale, Hôpital Purpan, CHU de Toulouse, Toulouse, France.,Centre de Référence du syndrome de Marfan et des syndromes apparentés, Hôpital des Enfants, CHU de Toulouse, Toulouse, France
| | - Thomas Edouard
- Centre de Référence du syndrome de Marfan et des syndromes apparentés, Hôpital des Enfants, CHU de Toulouse, Toulouse, France
| | - Yves Dulac
- Centre de Référence du syndrome de Marfan et des syndromes apparentés, Hôpital des Enfants, CHU de Toulouse, Toulouse, France
| | - Hélène Colineaux
- Département d'épidémiologie, d'économie de la santé et de santé publique, CHU de Toulouse, Toulouse, France.,LEASP UMR1027, INSERM, Université Toulouse III, Toulouse, France
| | - Maud Langeois
- Service de génétique médicale, Hôpital Purpan, CHU de Toulouse, Toulouse, France.,Centre de Référence du syndrome de Marfan et des syndromes apparentés, Hôpital des Enfants, CHU de Toulouse, Toulouse, France
| | - Nadine Hanna
- Centre de Référence pour le syndrome de Marfan et apparentés, AP-HP, Hôpital Bichat, Faculté Paris Diderot, LVTS INSERM U1148, Paris, France
| | - Catherine Boileau
- Centre de Référence pour le syndrome de Marfan et apparentés, AP-HP, Hôpital Bichat, Faculté Paris Diderot, LVTS INSERM U1148, Paris, France
| | - Pauline Arnaud
- Centre de Référence pour le syndrome de Marfan et apparentés, AP-HP, Hôpital Bichat, Faculté Paris Diderot, LVTS INSERM U1148, Paris, France
| | - Nicolas Chassaing
- Service de génétique médicale, Hôpital Purpan, CHU de Toulouse, Toulouse, France
| | - Sophie Julia
- Service de génétique médicale, Hôpital Purpan, CHU de Toulouse, Toulouse, France
| | - Guillaume Jondeau
- Centre de Référence pour le syndrome de Marfan et apparentés, AP-HP, Hôpital Bichat, Faculté Paris Diderot, LVTS INSERM U1148, Paris, France
| | - Aurélie Plancke
- UF de Génétique Médicale et Cytogénétique, Centre Hospitalier Régional Universitaire de Nîmes, Nîmes, France
| | - Philippe Khau Van Kien
- UF de Génétique Médicale et Cytogénétique, Centre Hospitalier Régional Universitaire de Nîmes, Nîmes, France
| | - Julie Plaisancié
- Service de génétique médicale, Hôpital Purpan, CHU de Toulouse, Toulouse, France.,Centre de Référence du syndrome de Marfan et des syndromes apparentés, Hôpital des Enfants, CHU de Toulouse, Toulouse, France
| |
Collapse
|
11
|
Jourdain A, Petit F, Odou M, Balduyck M, Brunelle P, Dufour W, Boussion S, Brischoux‐Boucher E, Colson C, Dieux A, Gérard M, Ghoumid J, Giuliano F, Goldenberg A, Khau Van Kien P, Lehalle D, Morin G, Moutton S, Smol T, Vanlerberghe C, Manouvrier‐Hanu S, Escande F. Multiplex targeted high‐throughput sequencing in a series of 352 patients with congenital limb malformations. Hum Mutat 2019; 41:222-239. [DOI: 10.1002/humu.23912] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2019] [Revised: 08/31/2019] [Accepted: 09/05/2019] [Indexed: 12/15/2022]
Affiliation(s)
- Anne‐Sophie Jourdain
- Service de Biochimie et Biologie MoléculaireCHU LilleLille France
- EA7364 RADEMEUniv. LilleLille France
| | - Florence Petit
- EA7364 RADEMEUniv. LilleLille France
- Clinique de Génétique Guy FontaineCHU LilleLille France
| | - Marie‐Françoise Odou
- Service de Biochimie et Biologie MoléculaireCHU LilleLille France
- Faculty of Pharmacy, UMR995, LIRIC (Lille Inflammation Research International Center)University of LilleLille France
| | - Malika Balduyck
- Service de Biochimie et Biologie MoléculaireCHU LilleLille France
- EA7364 RADEMEUniv. LilleLille France
| | - Perrine Brunelle
- Service de Biochimie et Biologie MoléculaireCHU LilleLille France
- Clinique de Génétique Guy FontaineCHU LilleLille France
| | | | | | | | | | - Anne Dieux
- Clinique de Génétique Guy FontaineCHU LilleLille France
| | | | - Jamal Ghoumid
- EA7364 RADEMEUniv. LilleLille France
- Clinique de Génétique Guy FontaineCHU LilleLille France
| | | | | | | | - Daphné Lehalle
- Reference Center for Developmental Anomalies, Department of Medical GeneticsDijon University HospitalDijon France
| | - Gilles Morin
- Centre d'activité de Génétique et d'OncogénétiqueCHU Amiens PicardieAmiens France
| | - Sébastien Moutton
- Reference Center for Developmental Anomalies, Department of Medical GeneticsDijon University HospitalDijon France
| | - Thomas Smol
- EA7364 RADEMEUniv. LilleLille France
- Institut de Génétique MédicaleCHU LilleLille France
| | - Clémence Vanlerberghe
- EA7364 RADEMEUniv. LilleLille France
- Clinique de Génétique Guy FontaineCHU LilleLille France
| | - Sylvie Manouvrier‐Hanu
- EA7364 RADEMEUniv. LilleLille France
- Clinique de Génétique Guy FontaineCHU LilleLille France
| | - Fabienne Escande
- Service de Biochimie et Biologie MoléculaireCHU LilleLille France
- EA7364 RADEMEUniv. LilleLille France
| |
Collapse
|
12
|
Margot H, Boursier G, Duflos C, Sanchez E, Amiel J, Andrau JC, Arpin S, Brischoux-Boucher E, Boute O, Burglen L, Caille C, Capri Y, Collignon P, Conrad S, Cormier-Daire V, Delplancq G, Dieterich K, Dollfus H, Fradin M, Faivre L, Fernandes H, Francannet C, Gatinois V, Gerard M, Goldenberg A, Ghoumid J, Grotto S, Guerrot AM, Guichet A, Isidor B, Jacquemont ML, Julia S, Khau Van Kien P, Legendre M, Le Quan Sang KH, Leheup B, Lyonnet S, Magry V, Manouvrier S, Martin D, Morel G, Munnich A, Naudion S, Odent S, Perrin L, Petit F, Philip N, Rio M, Robbe J, Rossi M, Sarrazin E, Toutain A, Van Gils J, Vera G, Verloes A, Weber S, Whalen S, Sanlaville D, Lacombe D, Aladjidi N, Geneviève D. Immunopathological manifestations in Kabuki syndrome: a registry study of 177 individuals. Genet Med 2019; 22:181-188. [PMID: 31363182 DOI: 10.1038/s41436-019-0623-x] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2019] [Accepted: 07/18/2019] [Indexed: 01/20/2023] Open
Abstract
PURPOSE Kabuki syndrome (KS) (OMIM 147920 and 300867) is a rare genetic disorder characterized by specific facial features, intellectual disability, and various malformations. Immunopathological manifestations seem prevalent and increase the morbimortality. To assess the frequency and severity of the manifestations, we measured the prevalence of immunopathological manifestations as well as genotype-phenotype correlations in KS individuals from a registry. METHODS Data were for 177 KS individuals with KDM6A or KMT2D pathogenic variants. Questionnaires to clinicians were used to assess the presence of immunodeficiency and autoimmune diseases both on a clinical and biological basis. RESULTS Overall, 44.1% (78/177) and 58.2% (46/79) of KS individuals exhibited infection susceptibility and hypogammaglobulinemia, respectively; 13.6% (24/177) had autoimmune disease (AID; 25.6% [11/43] in adults), 5.6% (10/177) with ≥2 AID manifestations. The most frequent AID manifestations were immune thrombocytopenic purpura (7.3% [13/177]) and autoimmune hemolytic anemia (4.0% [7/177]). Among nonhematological manifestations, vitiligo was frequent. Immune thrombocytopenic purpura was frequent with missense versus other types of variants (p = 0.027). CONCLUSION The high prevalence of immunopathological manifestations in KS demonstrates the importance of systematic screening and efficient preventive management of these treatable and sometimes life-threatening conditions.
Collapse
Affiliation(s)
- Henri Margot
- Service de génétique médicale, CHU de Bordeaux, Bordeaux, France
| | - Guilaine Boursier
- Département de génétique médicale, Maladies rares et médecine personnalisée, CHU de Montpellier, Montpellier, France.,INSERM U1183, Université de Montpellier, Montpellier, France
| | - Claire Duflos
- Département d'Information Médicale, CHU Montpellier, Montpellier, France
| | - Elodie Sanchez
- Département de génétique médicale, Maladies rares et médecine personnalisée, CHU de Montpellier, Montpellier, France.,INSERM U1183, Université de Montpellier, Montpellier, France
| | - Jeanne Amiel
- Fédération de Génétique et Institut Imagine, Hôpital Necker-Enfants Malades, AP-HP et INSERM UMR1163, Paris Descartes-Sorbonne Paris Cité University, Paris, France
| | - Jean-Christophe Andrau
- Institut de Génétique Moléculaire de Montpellier (IGMM), Univ Montpellier, Montpellier, France
| | - Stéphanie Arpin
- Service de génétique, CHU de Tours, UMR 1253, iBrain, Université de Tours, Inserm, Tours, France
| | | | - Odile Boute
- Centre de référence maladies rares pour les anomalies du développement Nord-Ouest, Clinique de Génétique médicale, CHU de Lille et EA7364, Université de Lille, Lille, France
| | - Lydie Burglen
- Centre de référence des malformations et maladies congénitales du cervelet, département de génétique et embryologie médicale, APHP, GHUEP, Hôpital Trousseau, Paris, France
| | | | - Yline Capri
- Service de génétique médicale, AP-HP Robert-Debré, Paris, France
| | | | - Solène Conrad
- Service de génétique médicale, CHU de Nantes, Nantes, France
| | - Valérie Cormier-Daire
- Fédération de Génétique et Institut Imagine, Hôpital Necker-Enfants Malades, AP-HP et INSERM UMR1163, Paris Descartes-Sorbonne Paris Cité University, Paris, France
| | - Geoffroy Delplancq
- Centre de Génétique Humaine, Université de Franche-Comté, Besançon, France
| | - Klaus Dieterich
- Service de génétique médicale, CHU de Grenoble, Grenoble, France
| | - Hélène Dollfus
- Service de génétique médicale, CHU de Strasbourg, Strasbourg, France
| | - Mélanie Fradin
- Service de génétique clinique, CHU de Rennes, Univ. Rennes, Institute of Genetics and Development of Rennes (IGDR) UMR6290 CNRS, Rennes, France
| | - Laurence Faivre
- Service de génétique médicale et centre de référence Anomalies du Développement et Syndromes Malformatifs, CHU de Dijon, Dijon, France
| | - Helder Fernandes
- Service d'onco hématologie pédiatrique, CHU de Bordeaux, Bordeaux, France.,Centre de référence des cytopénies auto-immunes de l'enfant, CHU de Bordeaux, Bordeaux, France.,INSERM CICP, Université de Bordeaux, Bordeaux, France
| | | | - Vincent Gatinois
- Département de génétique médicale, Maladies rares et médecine personnalisée, CHU de Montpellier, Montpellier, France.,INSERM U1183, Université de Montpellier, Montpellier, France
| | - Marion Gerard
- Service de génétique médicale, CHU de Caen, Caen, France
| | - Alice Goldenberg
- Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Department of Genetics and Reference Center for Developmental Disorders, F 76000, Normandy Center for Genomic and Personalized Medicine, Rouen, France
| | - Jamal Ghoumid
- Centre de référence maladies rares pour les anomalies du développement Nord-Ouest, Clinique de Génétique médicale, CHU de Lille et EA7364, Université de Lille, Lille, France
| | - Sarah Grotto
- Service de génétique médicale, AP-HP Robert-Debré, Paris, France
| | - Anne-Marie Guerrot
- Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Department of Genetics and Reference Center for Developmental Disorders, F 76000, Normandy Center for Genomic and Personalized Medicine, Rouen, France
| | - Agnès Guichet
- Service de génétique médicale, CHU d'Angers, Angers, France
| | - Bertrand Isidor
- Service de génétique médicale, CHU de Nantes, Nantes, France
| | - Marie-Line Jacquemont
- Service de génétique médicale, CHU de la Reunion, Saint-Pierre, France.,Centre de Référence Anomalies du développement et Syndromes malformatifs du Sud-Ouest Occitanie Réunion, Saint-Pierre, France
| | - Sophie Julia
- Service de génétique médicale, CHU de Toulouse, Toulouse, France
| | | | - Marine Legendre
- Service de génétique médicale, CHU de Bordeaux, Bordeaux, France.,Centre de Référence Anomalies du développement et Syndromes malformatifs du Sud-Ouest Occitanie Réunion, Saint-Pierre, France
| | - K H Le Quan Sang
- Institut Imagine, Paris Descartes-Sorbonne Paris Cité University, Paris, France
| | - Bruno Leheup
- Service de génétique médicale, CHU de Nancy, Nancy, France
| | - Stanislas Lyonnet
- Fédération de Génétique et Institut Imagine, Hôpital Necker-Enfants Malades, AP-HP et INSERM UMR1163, Paris Descartes-Sorbonne Paris Cité University, Paris, France
| | - Virginie Magry
- Service de génétique médicale, CHU de Clemont-Ferrand, Clermont-Ferrand, France
| | - Sylvie Manouvrier
- Centre de référence maladies rares pour les anomalies du développement Nord-Ouest, Clinique de Génétique médicale, CHU de Lille et EA7364, Université de Lille, Lille, France
| | | | | | - Arnold Munnich
- Fédération de Génétique et Institut Imagine, Hôpital Necker-Enfants Malades, AP-HP et INSERM UMR1163, Paris Descartes-Sorbonne Paris Cité University, Paris, France
| | - Sophie Naudion
- Service de génétique médicale, CHU de Bordeaux, Bordeaux, France.,Centre de Référence Anomalies du développement et Syndromes malformatifs du Sud-Ouest Occitanie Réunion, Saint-Pierre, France
| | - Sylvie Odent
- Service de génétique clinique, CHU de Rennes, Univ. Rennes, Institute of Genetics and Development of Rennes (IGDR) UMR6290 CNRS, Rennes, France
| | - Laurence Perrin
- Service de génétique médicale, AP-HP Robert-Debré, Paris, France
| | - Florence Petit
- Centre de référence maladies rares pour les anomalies du développement Nord-Ouest, Clinique de Génétique médicale, CHU de Lille et EA7364, Université de Lille, Lille, France
| | - Nicole Philip
- Service de génétique médicale, CHU de Marseille, Marseille, France
| | - Marlène Rio
- Fédération de Génétique et Institut Imagine, Hôpital Necker-Enfants Malades, AP-HP et INSERM UMR1163, Paris Descartes-Sorbonne Paris Cité University, Paris, France
| | - Julie Robbe
- Service de génétique médicale, CHU de Marseille, Marseille, France
| | | | - Elisabeth Sarrazin
- Centre de Référence Anomalies du développement et Syndromes malformatifs du Sud-Ouest Occitanie Réunion, Saint-Pierre, France
| | - Annick Toutain
- Service de génétique, CHU de Tours, UMR 1253, iBrain, Université de Tours, Inserm, Tours, France
| | - Julien Van Gils
- Service de génétique médicale, CHU de Bordeaux, Bordeaux, France.,Centre de Référence Anomalies du développement et Syndromes malformatifs du Sud-Ouest Occitanie Réunion, Saint-Pierre, France.,INSERM U1211, Université de Bordeaux, Bordeaux, France
| | - Gabriella Vera
- Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Department of Genetics and Reference Center for Developmental Disorders, F 76000, Normandy Center for Genomic and Personalized Medicine, Rouen, France
| | - Alain Verloes
- Service de génétique médicale, AP-HP Robert-Debré, Paris, France
| | - Sacha Weber
- Service de génétique médicale, CHU de Caen, Caen, France
| | - Sandra Whalen
- Service de génétique médicale, AP-HP Pitié Salpétrière, Paris, France
| | | | - Didier Lacombe
- Service de génétique médicale, CHU de Bordeaux, Bordeaux, France.,Centre de Référence Anomalies du développement et Syndromes malformatifs du Sud-Ouest Occitanie Réunion, Saint-Pierre, France.,INSERM U1211, Université de Bordeaux, Bordeaux, France
| | - Nathalie Aladjidi
- Service d'onco hématologie pédiatrique, CHU de Bordeaux, Bordeaux, France.,Centre de référence des cytopénies auto-immunes de l'enfant, CHU de Bordeaux, Bordeaux, France.,INSERM CICP, Université de Bordeaux, Bordeaux, France
| | - David Geneviève
- Département de génétique médicale, Maladies rares et médecine personnalisée, CHU de Montpellier, Montpellier, France. .,INSERM U1183, Université de Montpellier, Montpellier, France.
| |
Collapse
|
13
|
Beyens A, Moreno-Artero E, Bodemer C, Cox H, Gezdirici A, Yilmaz Gulec E, Kahloul N, Khau Van Kien P, Ogur G, Harroche A, Vasse M, Salhi A, Symoens S, Hadj-Rabia S, Callewaert B. ATP6V0A2-related cutis laxa in 10 novel patients: Focus on clinical variability and expansion of the phenotype. Exp Dermatol 2018; 28:1142-1145. [PMID: 29952037 DOI: 10.1111/exd.13723] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/22/2018] [Indexed: 01/11/2023]
Abstract
In ATP6V0A2-related cutis laxa, the skin phenotype varies from a wrinkly skin to prominent cutis laxa and typically associates with skeletal and neurological manifestations. The phenotype remains incompletely characterized, especially in adult patients. Glycosylation defects and reduced acidification of secretory vesicles contribute to the pathogenesis, but the consequences at the clinical level remain to be determined. Moreover, the morphology of the elastic fibres has not been studied in ATP6V0A2-related cutis laxa, nor its relation with potential clinical risks. We report on the extreme variability in ATP6V0A2-related cutis laxa in 10 novel patients, expand the phenotype with emphysema and von Willebrand disease and hypothesize on the pathogenesis that might link both with deficiency of glycosylation and with elastic fibre anomalies. Our data will affect clinical management of patients with ATP6V0A2-related cutis laxa.
Collapse
Affiliation(s)
- Aude Beyens
- Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium
| | - Ester Moreno-Artero
- Reference Centre for Genodermatoses and Rare Skin Diseases (MAGEC) & Department of Dermatology, Department of Paediatric Social Work, INSERM U1163 & Institut Imagine, Hôpital Universitaire Necker-Enfants Malades, APHP, Université Paris Descartes - Sorbonne Paris Cité, Paris, France
| | - Christine Bodemer
- Reference Centre for Genodermatoses and Rare Skin Diseases (MAGEC) & Department of Dermatology, Department of Paediatric Social Work, INSERM U1163 & Institut Imagine, Hôpital Universitaire Necker-Enfants Malades, APHP, Université Paris Descartes - Sorbonne Paris Cité, Paris, France
| | - Helen Cox
- West Midlands Regional Clinical Genetics Service, Clinical Genetics Unit, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK
| | - Alper Gezdirici
- Department of Medical Genetics, Kanuni Sultan Suleyman Training and Research Hospital, Health Sciences University, Istanbul, Turkey
| | - Elif Yilmaz Gulec
- Department of Medical Genetics, Kanuni Sultan Suleyman Training and Research Hospital, Health Sciences University, Istanbul, Turkey
| | - Najoua Kahloul
- Center for Pediatrics, CHU Farhat Hached De Sousse, Sousse, Tunisia
| | - Philippe Khau Van Kien
- Department of Medical Genetics, Centre Hospitalier Régional Universitaire de Nîmes, Nîmes, France
| | - Gonul Ogur
- Department of Pediatric Genetics, Faculty of Medicine, Ondokuz Mayis University, Samsun, Turkey
| | - Annie Harroche
- Service d'Hématologie Clinique, Centre de Traitement de l'Hémophilie, Hôpital Universitaire Necker-Enfants Malades, Paris, France
| | - Marc Vasse
- Department of Clinical Biology & INSERM UMR-S1176, Foch Hospital, Suresnes, Le Kremlin-Bicêtre, France
| | - Aïcha Salhi
- Service de Dermatologie, Faculté de Médecine d'Alger, Université d'Alger, Alger, Algeria
| | - Sofie Symoens
- Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium
| | - Smail Hadj-Rabia
- Reference Centre for Genodermatoses and Rare Skin Diseases (MAGEC) & Department of Dermatology, Department of Paediatric Social Work, INSERM U1163 & Institut Imagine, Hôpital Universitaire Necker-Enfants Malades, APHP, Université Paris Descartes - Sorbonne Paris Cité, Paris, France
| | - Bert Callewaert
- Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium
| |
Collapse
|
14
|
Guissart C, Tran Mau Them F, Debant V, Viart V, Dubucs C, Pritchard V, Rouzier C, Boureau-Wirth A, Haquet E, Puechberty J, Bieth E, Khau Van Kien P, Brechard MP, Raynal C, Girardet A, Claustres M, Koenig M, Vincent MC. A Broad Test Based on Fluorescent-Multiplex PCR for Noninvasive Prenatal Diagnosis of Cystic Fibrosis. Fetal Diagn Ther 2018; 45:403-412. [PMID: 30121677 DOI: 10.1159/000489776] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2018] [Accepted: 05/02/2018] [Indexed: 11/19/2022]
Abstract
BACKGROUND Analysis of cell-free fetal DNA in maternal plasma is very promising for early diagnosis of monogenic diseases. However, it has been limited by the need to set up patient- or disease-specific custom-made approaches. Here we propose a universal test based on fluorescent multiplex PCR and size fragment analysis for an indirect diagnosis of cystic fibrosis (CF). METHODS The test, based on haplotyping, includes nine intra- and extragenic short tandem repeats of the CFTR locus, the coamplification of p.Phe508del (the most frequent mutation in CF patients worldwide), and a specific SRY sequence. The assay is able to determine the inherited paternal allele. RESULTS Our simple approach was successfully applied to 30 couples and provided clear results from the maternal plasma. The mean rate of informative markers was sufficient to propose it for use in indirect diagnosis. CONCLUSIONS This noninvasive prenatal diagnosis test, focused on indirect diagnosis of CF, offers many advantages over current methods: it is simple, rapid, and cost-effective. It allows for the testing of a large number of couples with high risk of CF, whatever the familial mutation of the CFTR gene. It provides an alternative method to reduce the number of invasive tests.
Collapse
Affiliation(s)
- Claire Guissart
- Laboratoire de Génétique Moléculaire, IURC, CHRU de Montpellier, Montpellier, France.,Equipe Accueil EA7402, Université Montpellier, Montpellier, France
| | | | - Vanessa Debant
- Laboratoire de Génétique Moléculaire, IURC, CHRU de Montpellier, Montpellier, France
| | - Victoria Viart
- Laboratoire de Génétique Moléculaire, IURC, CHRU de Montpellier, Montpellier, France
| | - Charlotte Dubucs
- Laboratoire de Génétique Moléculaire, IURC, CHRU de Montpellier, Montpellier, France
| | | | - Cécile Rouzier
- CHU de Nice, Service de Génétique Médicale, Nice, France
| | | | - Emmanuelle Haquet
- CHU de Montpellier, Service de Génétique Médicale, Montpellier, France
| | | | - Eric Bieth
- CHU de Toulouse, Service de Génétique Médicale, Toulouse, France
| | | | | | - Caroline Raynal
- Laboratoire de Génétique Moléculaire, IURC, CHRU de Montpellier, Montpellier, France.,Equipe Accueil EA7402, Université Montpellier, Montpellier, France
| | - Anne Girardet
- Laboratoire de Génétique Moléculaire, IURC, CHRU de Montpellier, Montpellier, France.,Equipe Accueil EA7402, Université Montpellier, Montpellier, France
| | - Mireille Claustres
- Laboratoire de Génétique Moléculaire, IURC, CHRU de Montpellier, Montpellier, France.,Equipe Accueil EA7402, Université Montpellier, Montpellier, France
| | - Michel Koenig
- Laboratoire de Génétique Moléculaire, IURC, CHRU de Montpellier, Montpellier, France.,Equipe Accueil EA7402, Université Montpellier, Montpellier, France
| | - Marie-Claire Vincent
- Laboratoire de Génétique Moléculaire, IURC, CHRU de Montpellier, Montpellier, France, .,Equipe Accueil EA7402, Université Montpellier, Montpellier, France,
| |
Collapse
|
15
|
Renard D, Taieb G, Garibaldi M, Maues De Paula A, Bernard R, Lagha N, Cristofari G, Vovan C, Chaix C, Lévy N, Khau Van Kien P, Sacconi S. Inflammatory facioscapulohumeral muscular dystrophy type 2 in 18p deletion syndrome. Am J Med Genet A 2018; 176:1760-1763. [PMID: 30055030 DOI: 10.1002/ajmg.a.38843] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2017] [Revised: 03/30/2018] [Accepted: 04/23/2018] [Indexed: 02/06/2023]
Abstract
Facioscapulohumeral muscular dystrophy (FSHD) has been shown to be related to genetic and epigenetic derepression of DUX4 (mapping to chromosome 4), a gene located within a repeat array of D4Z4 sequences of polymorphic length. FSHD type 1 (FSHD1) is associated with pathogenic D4Z4 repeat array contraction, while FSHD type 2 (FSHD2) is associated with SMCHD1 variants (a chromatin modifier gene that maps to the short arm of chromosome 18). Both FSHD types require permissive polyadenylation signal (4qA) downstream of the D4Z4 array.
Collapse
Affiliation(s)
- Dimitri Renard
- Department of Neurology, CHU Nîmes, Hôpital Caremeau, Nîmes, France
| | - Guillaume Taieb
- Department of Neurology, CHU Nîmes, Hôpital Caremeau, Nîmes, France
| | - Matteo Garibaldi
- Peripheral Nervous System, Muscle and ALS Department, Nice University Hospital, Université Côte d'Azur, Nice, France.,Faculty of Medicine and Psychology, Sapienza University of Rome, Rome, Italy
| | - Andre Maues De Paula
- Neuropathology Laboratory, Faculty of Medicine of Marseille, Assistance Publique-Hôpitaux de Marseille, La Timone Hospital, Marseille, France
| | - Rafaelle Bernard
- Medical Genetic Department, Assistance Publique-Hôpitaux de Marseille, La Timone Hospital; Aix-Marseille University, Marseille, France.,INSERM GMGF UMR_S910, Marseille, France
| | - Nadira Lagha
- Faculty of Medicine, Institute for Research on Cancer and Aging of Nice (IRCAN), INSERM U1081, CNRS UMR 7284, Université Côte d'Azur (UCA), Nice, France
| | - Gael Cristofari
- Faculty of Medicine, Institute for Research on Cancer and Aging of Nice (IRCAN), INSERM U1081, CNRS UMR 7284, Université Côte d'Azur (UCA), Nice, France.,University Hospital Federation (FHU) OncoAge, CHU-Nice, University of Nice Sophia Antipolis, Nice, France
| | - Catherine Vovan
- Medical Genetic Department, Assistance Publique-Hôpitaux de Marseille, La Timone Hospital; Aix-Marseille University, Marseille, France
| | - Charlène Chaix
- Medical Genetic Department, Assistance Publique-Hôpitaux de Marseille, La Timone Hospital; Aix-Marseille University, Marseille, France
| | - Nicolas Lévy
- Medical Genetic Department, Assistance Publique-Hôpitaux de Marseille, La Timone Hospital; Aix-Marseille University, Marseille, France.,INSERM GMGF UMR_S910, Marseille, France
| | | | - Sabrina Sacconi
- Peripheral Nervous System, Muscle and ALS Department, Nice University Hospital, Université Côte d'Azur, Nice, France.,Faculty of Medicine, Institute for Research on Cancer and Aging of Nice (IRCAN), INSERM U1081, CNRS UMR 7284, Université Côte d'Azur (UCA), Nice, France
| |
Collapse
|
16
|
De Tomasi L, David P, Humbert C, Silbermann F, Arrondel C, Tores F, Fouquet S, Desgrange A, Niel O, Bole-Feysot C, Nitschké P, Roume J, Cordier MP, Pietrement C, Isidor B, Khau Van Kien P, Gonzales M, Saint-Frison MH, Martinovic J, Novo R, Piard J, Cabrol C, Verma IC, Puri R, Journel H, Aziza J, Gavard L, Said-Menthon MH, Heidet L, Saunier S, Jeanpierre C. Mutations in GREB1L Cause Bilateral Kidney Agenesis in Humans and Mice. Am J Hum Genet 2017; 101:803-814. [PMID: 29100091 DOI: 10.1016/j.ajhg.2017.09.026] [Citation(s) in RCA: 65] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2017] [Accepted: 09/28/2017] [Indexed: 12/25/2022] Open
Abstract
Congenital anomalies of the kidney and urinary tract (CAKUT) constitute a major cause of chronic kidney disease in children and 20% of prenatally detected anomalies. CAKUT encompass a spectrum of developmental kidney defects, including renal agenesis, hypoplasia, and cystic and non-cystic dysplasia. More than 50 genes have been reported as mutated in CAKUT-affected case subjects. However, the pathophysiological mechanisms leading to bilateral kidney agenesis (BKA) remain largely elusive. Whole-exome or targeted exome sequencing of 183 unrelated familial and/or severe CAKUT-affected case subjects, including 54 fetuses with BKA, led to the identification of 16 heterozygous variants in GREB1L (growth regulation by estrogen in breast cancer 1-like), a gene reported as a target of retinoic acid signaling. Four loss-of-function and 12 damaging missense variants, 14 being absent from GnomAD, were identified. Twelve of them were present in familial or simplex BKA-affected case subjects. Female BKA-affected fetuses also displayed uterus agenesis. We demonstrated a significant association between GREB1L variants and BKA. By in situ hybridization, we showed expression of Greb1l in the nephrogenic zone in developing mouse kidney. We generated a Greb1l knock-out mouse model by CRISPR-Cas9. Analysis at E13.5 revealed lack of kidneys and genital tract anomalies in male and female Greb1l-/- embryos and a slight decrease in ureteric bud branching in Greb1l+/- embryos. We showed that Greb1l invalidation in mIMCD3 cells affected tubulomorphogenesis in 3D-collagen culture, a phenotype rescued by expression of the wild-type human protein. This demonstrates that GREB1L plays a major role in early metanephros and genital development in mice and humans.
Collapse
|
17
|
Vandervore L, Stouffs K, Tanyalçin I, Vanderhasselt T, Roelens F, Holder-Espinasse M, Jørgensen A, Pepin MG, Petit F, Khau Van Kien P, Bahi-Buisson N, Lissens W, Gheldof A, Byers PH, Jansen AC. Bi-allelic variants in COL3A1 encoding the ligand to GPR56 are associated with cobblestone-like cortical malformation, white matter changes and cerebellar cysts. J Med Genet 2017; 54:432-440. [PMID: 28258187 DOI: 10.1136/jmedgenet-2016-104421] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2016] [Revised: 01/17/2017] [Accepted: 01/19/2017] [Indexed: 12/24/2022]
Abstract
BACKGROUND Collagens are one of the major constituents of the pial membrane, which plays a crucial role in neuronal migration and cortical lamination during brain development. Type III procollagen, the chains of which are encoded by COL3A1, is the ligand of the G protein-coupled receptor 56 (GPR56), also known as adhesion G protein-coupled receptor G1. Bi-allelic mutations in GPR56 give rise to cobblestone-like malformation, white matter changes and cerebellar dysplasia. This report shows that bi-allelic mutations in COL3A1 are associated with a similar phenotype. METHODS Exome analysis was performed in a family consisting of two affected and two non-affected siblings. Brain imaging studies of this family and of two previously reported individuals with bi-allelic mutations in COL3A1 were reviewed. Functional assays were performed on dermal fibroblasts. RESULTS Exome analysis revealed a novel homozygous variant c.145C>G (p.Pro49Ala) in exon 2 of COL3A1. Brain MRI in the affected siblings as well as in the two previously reported individuals with bi-allelic COL3A1 mutations showed a brain phenotype similar to that associated with mutations in GPR56. CONCLUSION Homozygous or compound heterozygous mutations in COL3A1 are associated with cobblestone-like malformation in all three families reported to date. The variability of the phenotype across patients suggests that genetic alterations in distinct domains of type III procollagen can lead to different outcomes. The presence of cobblestone-like malformation in patients with bi-allelic COL3A1 mutations emphasises the critical role of the type III collagen-GPR56 axis and the pial membrane in the regulation of brain development and cortical lamination.
Collapse
Affiliation(s)
- Laura Vandervore
- Neurogenetics Research Group, Research Cluster Reproduction, Genetics and Regenerative Medicine, Vrije Universiteit Brussel, Brussels, Belgium.,Center for Medical Genetics, UZ Brussel, Brussels, Belgium
| | - Katrien Stouffs
- Neurogenetics Research Group, Research Cluster Reproduction, Genetics and Regenerative Medicine, Vrije Universiteit Brussel, Brussels, Belgium.,Center for Medical Genetics, UZ Brussel, Brussels, Belgium
| | - Ibrahim Tanyalçin
- Neurogenetics Research Group, Research Cluster Reproduction, Genetics and Regenerative Medicine, Vrije Universiteit Brussel, Brussels, Belgium.,Center for Medical Genetics, UZ Brussel, Brussels, Belgium
| | | | - Filip Roelens
- Department of Pediatric Neurology, AZ Delta, Roeselare, Belgium
| | | | - Agnete Jørgensen
- Division of Child and Adolescent Health, Department of Medical Genetics, University Hospital of North Norway, Tromsø, Norway
| | - Melanie G Pepin
- Department of Pathology, University of Washington, Seattle, Washington, USA
| | - Florence Petit
- Service de Génétique Clinique, Hôpital J. de Flandre, Lille, France
| | | | - Nadia Bahi-Buisson
- Institut Imagine, Université Paris Descartes - Sorbonne Paris Cités, Paris, France
| | - Willy Lissens
- Neurogenetics Research Group, Research Cluster Reproduction, Genetics and Regenerative Medicine, Vrije Universiteit Brussel, Brussels, Belgium.,Center for Medical Genetics, UZ Brussel, Brussels, Belgium
| | - Alexander Gheldof
- Neurogenetics Research Group, Research Cluster Reproduction, Genetics and Regenerative Medicine, Vrije Universiteit Brussel, Brussels, Belgium.,Center for Medical Genetics, UZ Brussel, Brussels, Belgium
| | - Peter H Byers
- Department of Pathology, University of Washington, Seattle, Washington, USA.,Department of Medicine (Medical Genetics), University of Washington, Seattle, USA
| | - Anna C Jansen
- Neurogenetics Research Group, Research Cluster Reproduction, Genetics and Regenerative Medicine, Vrije Universiteit Brussel, Brussels, Belgium.,Department of Pediatrics, Pediatric Neurology Unit, UZ Brussel, Brussels, Belgium
| |
Collapse
|
18
|
Capet N, Dimitri R, Feasson L, Manel V, Echaniz-Laguna A, Kien PKV, Sacconi S. Dystrophie Musculaire Facio-Scapulo-Humérale (DMFSH) associée au syndrome de délétion du chromosome 18 (18p-). Rev Neurol (Paris) 2017. [DOI: 10.1016/j.neurol.2017.01.096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
19
|
Kuentz P, St-Onge J, Duffourd Y, Courcet JB, Carmignac V, Jouan T, Sorlin A, Abasq-Thomas C, Albuisson J, Amiel J, Amram D, Arpin S, Attie-Bitach T, Bahi-Buisson N, Barbarot S, Baujat G, Bessis D, Boccara O, Bonnière M, Boute O, Bursztejn AC, Chiaverini C, Cormier-Daire V, Coubes C, Delobel B, Edery P, Chehadeh SE, Francannet C, Geneviève D, Goldenberg A, Haye D, Isidor B, Jacquemont ML, Khau Van Kien P, Lacombe D, Martin L, Martinovic J, Maruani A, Mathieu-Dramard M, Mazereeuw-Hautier J, Michot C, Mignot C, Miquel J, Morice-Picard F, Petit F, Phan A, Rossi M, Touraine R, Verloes A, Vincent M, Vincent-Delorme C, Whalen S, Willems M, Marle N, Lehalle D, Thevenon J, Thauvin-Robinet C, Hadj-Rabia S, Faivre L, Vabres P, Rivière JB. Molecular diagnosis of PIK3CA-related overgrowth spectrum (PROS) in 162 patients and recommendations for genetic testing. Genet Med 2017; 19:989-997. [DOI: 10.1038/gim.2016.220] [Citation(s) in RCA: 70] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2016] [Accepted: 11/23/2016] [Indexed: 01/19/2023] Open
|
20
|
Goldenberg A, Riccardi F, Tessier A, Pfundt R, Busa T, Cacciagli P, Capri Y, Coutton C, Delahaye-Duriez A, Frebourg T, Gatinois V, Guerrot AM, Genevieve D, Lecoquierre F, Jacquette A, Khau Van Kien P, Leheup B, Marlin S, Verloes A, Michaud V, Nadeau G, Mignot C, Parent P, Rossi M, Toutain A, Schaefer E, Thauvin-Robinet C, Van Maldergem L, Thevenon J, Satre V, Perrin L, Vincent-Delorme C, Sorlin A, Missirian C, Villard L, Mancini J, Saugier-Veber P, Philip N. Clinical and molecular findings in 39 patients with KBG syndrome caused by deletion or mutation of ANKRD11. Am J Med Genet A 2016; 170:2847-2859. [PMID: 27605097 DOI: 10.1002/ajmg.a.37878] [Citation(s) in RCA: 52] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2016] [Accepted: 07/19/2016] [Indexed: 12/28/2022]
Abstract
KBG syndrome, due to ANKRD11 alteration is characterized by developmental delay, short stature, dysmorphic facial features, and skeletal anomalies. We report a clinical and molecular study of 39 patients affected by KBG syndrome. Among them, 19 were diagnosed after the detection of a 16q24.3 deletion encompassing the ANKRD11 gene by array CGH. In the 20 remaining patients, the clinical suspicion was confirmed by the identification of an ANKRD11 mutation by direct sequencing. We present arguments to modulate the previously reported diagnostic criteria. Macrodontia should no longer be considered a mandatory feature. KBG syndrome is compatible with autonomous life in adulthood. Autism is less frequent than previously reported. We also describe new clinical findings with a potential impact on the follow-up of patients, such as precocious puberty and a case of malignancy. Most deletions remove the 5'end or the entire coding region but never extend toward 16q telomere suggesting that distal 16q deletion could be lethal. Although ANKRD11 appears to be a major gene associated with intellectual disability, KBG syndrome remains under-diagnosed. NGS-based approaches for sequencing will improve the detection of point mutations in this gene. Broad knowledge of the clinical phenotype is essential for a correct interpretation of the molecular results. © 2016 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Alice Goldenberg
- Service de génétique, CHU de Rouen et Inserm U1079, Université de Rouen, Centre Normand de Génomique Médicale et Médecine Personnalisée, Rouen, France.
| | - Florence Riccardi
- Département de génétique médicale, Hôpital de la Timone-Enfant, Assistance publique hôpitaux de Marseille, Marseille, France
| | - Aude Tessier
- Service de génétique, CHU de Rouen et Inserm U1079, Université de Rouen, Centre Normand de Génomique Médicale et Médecine Personnalisée, Rouen, France
| | - Rolph Pfundt
- Afdeling Genetica, Radboud universitair medisch centrum, Nijmegen, Holland
| | - Tiffany Busa
- Département de génétique médicale, Hôpital de la Timone-Enfant, Assistance publique hôpitaux de Marseille, Marseille, France
| | | | - Yline Capri
- Unité fonctionnelle de génétique clinique, CHU Robert Debré, Paris, France
| | - Charles Coutton
- Unité fonctionnelle de génétique chromosomique, Hôpital Couple-Enfant, CHU de Grenoble, Université de Grenoble Alpes, INSERM 1209, CNRS UMR 5309, Grenoble, France
| | - Andree Delahaye-Duriez
- Laboratoire d'histologie-embryologie-cytogénétique-BDR, Hôpital Jean Verdier, CHU de Paris Seine-Saint-Denis, APHP et Université Paris 13, Sorbonne Paris Cité, Bondy, France
| | - Thierry Frebourg
- Service de génétique, CHU de Rouen et Inserm U1079, Université de Rouen, Centre Normand de Génomique Médicale et Médecine Personnalisée, Rouen, France
| | - Vincent Gatinois
- Laboratoire de génétique des maladies rares et auto-inflammatoires, Hôpital Arnaud de Villeneuve, CHRU de Montpellier, Montpellier, France
| | - Anne-Marie Guerrot
- Service de génétique, CHU de Rouen et Inserm U1079, Université de Rouen, Centre Normand de Génomique Médicale et Médecine Personnalisée, Rouen, France
| | - David Genevieve
- Département de génétique médicale, Hôpital Arnaud de Villeneuve, CHRU de Montpellier, Montpellier, France
| | - Francois Lecoquierre
- Service de génétique, CHU de Rouen et Inserm U1079, Université de Rouen, Centre Normand de Génomique Médicale et Médecine Personnalisée, Rouen, France
| | - Aurélia Jacquette
- APHP, Département de Génétique, Centre de référence déficiences intellectuelles de Causes Rares, GRC UPMC "déficiences intellectuelles et autisme", Groupe Hospitalier Pitié Salpêtrière, Paris, France
| | - Philippe Khau Van Kien
- Unité fonctionnelle de génétique médicale et cytogénétique, Hôpital Caremeau, CHU de Nîmes, Nîmes, France
| | - Bruno Leheup
- Service de génétique clinique, Hôpital de Brabois, CHU de Nancy, Nancy, France
| | - Sandrine Marlin
- Service de génétique, Hôpital Necker-Enfants Malades, Paris, France
| | - Alain Verloes
- Unité fonctionnelle de génétique clinique, CHU Robert Debré, Paris, France
| | - Vincent Michaud
- Service de génétique médicale, GH Pellegrin, CHU de Bordeaux, Bordeaux, France
| | - Gwenael Nadeau
- Unité fonctionnelle de cytogénétique, CH de Valence, Valence, France
| | - Cyril Mignot
- APHP, Département de Génétique, Centre de référence déficiences intellectuelles de Causes Rares, GRC UPMC "déficiences intellectuelles et autisme", Groupe Hospitalier Pitié Salpêtrière, Paris, France
| | - Philippe Parent
- Département de pédiatrie et génétique médicale, Hôpital Morvan, CHRU de Brest, Brest, France
| | - Massimiliano Rossi
- Service de génétique, Hôpital Femme-Mère-Enfant, GH Est, CHU de Lyon, Lyon, France
| | - Annick Toutain
- Service de génétique, Hôpital Bretonneau, CHRU de Tours, Tours, France
| | - Elise Schaefer
- Service de génétique médicale, Hôpital de Hautepierre, CHU de Strasbourg, Strasbourg, France
| | | | - Lionel Van Maldergem
- Centre de génétique humaine, Hôpital Saint-Jacques, CHRU de Besançon, Besançon, France
| | - Julien Thevenon
- Centre de génétique, Hôpital François Mitterrand, CHU Dijon Bourgogne, Dijon, France
| | - Véronique Satre
- Unité fonctionnelle de génétique chromosomique, Hôpital Couple-Enfant, CHU de Grenoble, Université de Grenoble Alpes, INSERM 1209, CNRS UMR 5309, Grenoble, France
| | - Laurence Perrin
- Unité fonctionnelle de génétique clinique, CHU Robert Debré, Paris, France
| | | | - Arthur Sorlin
- Service de génétique clinique, Hôpital de Brabois, CHU de Nancy, Nancy, France
| | - Chantal Missirian
- Département de génétique médicale, Hôpital de la Timone-Enfant, Assistance publique hôpitaux de Marseille, Marseille, France
| | | | - Julien Mancini
- Aix Marseille Université, Inserm, IRD, UMR_S912, SESSTIM, Marseille, France.,APHM, Hôpital de la Timone, BiosTIC, Marseille, France
| | - Pascale Saugier-Veber
- Service de génétique, CHU de Rouen et Inserm U1079, Université de Rouen, Centre Normand de Génomique Médicale et Médecine Personnalisée, Rouen, France
| | - Nicole Philip
- Département de génétique médicale, Hôpital de la Timone-Enfant, Assistance publique hôpitaux de Marseille, Marseille, France.,Aix Marseille Université, INSERM, GMGF, Marseille, France
| |
Collapse
|
21
|
Lefebvre M, Sanlaville D, Marle N, Thauvin-Robinet C, Gautier E, Chehadeh SE, Mosca-Boidron AL, Thevenon J, Edery P, Alex-Cordier MP, Till M, Lyonnet S, Cormier-Daire V, Amiel J, Philippe A, Romana S, Malan V, Afenjar A, Marlin S, Chantot-Bastaraud S, Bitoun P, Heron B, Piparas E, Morice-Picard F, Moutton S, Chassaing N, Vigouroux-Castera A, Lespinasse J, Manouvrier-Hanu S, Boute-Benejean O, Vincent-Delorme C, Petit F, Meur NL, Marti-Dramard M, Guerrot AM, Goldenberg A, Redon S, Ferrec C, Odent S, Caignec CL, Mercier S, Gilbert-Dussardier B, Toutain A, Arpin S, Blesson S, Mortemousque I, Schaefer E, Martin D, Philip N, Sigaudy S, Busa T, Missirian C, Giuliano F, Benailly HK, Kien PKV, Leheup B, Benneteau C, Lambert L, Caumes R, Kuentz P, François I, Heron D, Keren B, Cretin E, Callier P, Julia S, Faivre L. Genetic counselling difficulties and ethical implications of incidental findings from array-CGH: a 7-year national survey. Clin Genet 2016; 89:630-5. [PMID: 26582393 DOI: 10.1111/cge.12696] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2015] [Revised: 11/11/2015] [Accepted: 11/16/2015] [Indexed: 11/29/2022]
Abstract
Microarray-based comparative genomic hybridization (aCGH) is commonly used in diagnosing patients with intellectual disability (ID) with or without congenital malformation. Because aCGH interrogates with the whole genome, there is a risk of being confronted with incidental findings (IF). In order to anticipate the ethical issues of IF with the generalization of new genome-wide analysis technologies, we questioned French clinicians and cytogeneticists about the situations they have faced regarding IF from aCGH. Sixty-five IF were reported. Forty corresponded to autosomal dominant diseases with incomplete penetrance, 7 to autosomal dominant diseases with complete penetrance, 14 to X-linked diseases, and 4 were heterozygotes for autosomal recessive diseases with a high prevalence of heterozygotes in the population. Therapeutic/preventive measures or genetic counselling could be argued for all cases except four. These four IF were intentionally not returned to the patients. Clinicians reported difficulties in returning the results in 29% of the cases, mainly when the question of IF had not been anticipated. Indeed, at the time of the investigation, only 48% of the clinicians used consents mentioning the risk of IF. With the emergence of new technologies, there is a need to report such national experiences; they show the importance of pre-test information on IF.
Collapse
Affiliation(s)
- M Lefebvre
- Centre de Génétique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs de l'Est, FHU-TRANSLAD, Dijon, France.,Génétique des Anomalies du Développement, Université de Bourgogne, Dijon, France.,FHU-TRANSLAD, Université de Bourgogne, Dijon, France
| | - D Sanlaville
- Genetics Service, Hospices Civils de Lyon, Hôpital Femme-Mère-Enfant, and Eastern Biology and Pathology Centre, Lyon, France
| | - N Marle
- Centre de Génétique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs de l'Est, FHU-TRANSLAD, Dijon, France.,Génétique des Anomalies du Développement, Université de Bourgogne, Dijon, France
| | - C Thauvin-Robinet
- Centre de Génétique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs de l'Est, FHU-TRANSLAD, Dijon, France.,Génétique des Anomalies du Développement, Université de Bourgogne, Dijon, France.,FHU-TRANSLAD, Université de Bourgogne, Dijon, France
| | - E Gautier
- Centre de Génétique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs de l'Est, FHU-TRANSLAD, Dijon, France.,FHU-TRANSLAD, Université de Bourgogne, Dijon, France
| | - S E Chehadeh
- Centre de Génétique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs de l'Est, FHU-TRANSLAD, Dijon, France.,Génétique des Anomalies du Développement, Université de Bourgogne, Dijon, France
| | - A-L Mosca-Boidron
- Centre de Génétique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs de l'Est, FHU-TRANSLAD, Dijon, France.,Génétique des Anomalies du Développement, Université de Bourgogne, Dijon, France
| | - J Thevenon
- Centre de Génétique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs de l'Est, FHU-TRANSLAD, Dijon, France.,Génétique des Anomalies du Développement, Université de Bourgogne, Dijon, France.,FHU-TRANSLAD, Université de Bourgogne, Dijon, France
| | - P Edery
- Genetics Service, Hospices Civils de Lyon, Hôpital Femme-Mère-Enfant, and Eastern Biology and Pathology Centre, Lyon, France
| | - M-P Alex-Cordier
- Genetics Service, Hospices Civils de Lyon, Hôpital Femme-Mère-Enfant, and Eastern Biology and Pathology Centre, Lyon, France
| | - M Till
- Genetics Service, Hospices Civils de Lyon, Hôpital Femme-Mère-Enfant, and Eastern Biology and Pathology Centre, Lyon, France
| | - S Lyonnet
- Département de Génétique, Hôpital Necker-Enfants Malades, Paris, France
| | - V Cormier-Daire
- Département de Génétique, Hôpital Necker-Enfants Malades, Paris, France
| | - J Amiel
- Département de Génétique, Hôpital Necker-Enfants Malades, Paris, France
| | - A Philippe
- Département de Génétique, Hôpital Necker-Enfants Malades, Paris, France
| | - S Romana
- Département de Génétique, Hôpital Necker-Enfants Malades, Paris, France
| | - V Malan
- Département de Génétique, Hôpital Necker-Enfants Malades, Paris, France
| | - A Afenjar
- Service de Génétique, Hôpital Pitié Salpêtrière, Paris, France
| | - S Marlin
- Département de Génétique, Hôpital Necker-Enfants Malades, Paris, France
| | - S Chantot-Bastaraud
- APHP, Hôpital Armand Trousseau, Service de Génétique et d'Embryologie Médicales, Paris, France
| | - P Bitoun
- Service de Pédiatrie, Hôpital Jean Verdier, Assistance Publique - Hôpitaux de Paris, Paris, France
| | - B Heron
- Department of Neuropediatrics, Armand Trousseau Hospital, APHP, Paris, France
| | - E Piparas
- Cytogenetics Laboratory, Jean Verdier Hospital, Bondy, France
| | - F Morice-Picard
- Department of Clinical Genetics, Bordeaux Children's Hospital, CHU de Bordeaux, Bordeaux, France
| | - S Moutton
- Department of Clinical Genetics, Bordeaux Children's Hospital, CHU de Bordeaux, Bordeaux, France
| | - N Chassaing
- Service de Génétique Médicale, Hôpital Purpan, CHU Toulouse, Université Paul Sabatier Toulouse, Toulouse, France
| | - A Vigouroux-Castera
- Service de Génétique Médicale, Hôpital Purpan, CHU Toulouse, Université Paul Sabatier Toulouse, Toulouse, France
| | - J Lespinasse
- Cytogenetics Laboratory, Chambery Hospital, Chambery, France
| | - S Manouvrier-Hanu
- Service de Génétique Clinique, Hôpital Jeanne de Flandre, CHRU, Lille, France
| | - O Boute-Benejean
- Service de Génétique Clinique, Hôpital Jeanne de Flandre, CHRU, Lille, France
| | - C Vincent-Delorme
- Service de Génétique Clinique, Hôpital Jeanne de Flandre, CHRU, Lille, France
| | - F Petit
- Service de Génétique Clinique, Hôpital Jeanne de Flandre, CHRU, Lille, France
| | - N L Meur
- Cytogenetics Laboratory, Etablissement Français du Sang de Normandie, Rouen, France
| | - M Marti-Dramard
- Unité de Génétique Clinique, Hôpital Nord, CHU, Amiens, France
| | - A-M Guerrot
- Service de Pédiatrie Néonatale et Réanimation, Centre D'éducation Fonctionnelle de l'enfant, CHU de Rouen, Rouen, France
| | - A Goldenberg
- Unité de Génétique Médicale, CHU Rouen, Rouen, France
| | - S Redon
- Laboratoire de Génétique Moléculaire, CHU, Brest, France
| | - C Ferrec
- Laboratoire de Génétique Moléculaire, CHU, Brest, France
| | - S Odent
- Service de Génétique Clinique, CLAD-Ouest, Hôpital Sud, Rennes, France
| | - C L Caignec
- Service de Génétique Médicale, Unité de Génétique Clinique, CLAD-Ouest, CHU de Nantes, Nantes, France
| | - S Mercier
- Service de Génétique Médicale, Unité de Génétique Clinique, CLAD-Ouest, CHU de Nantes, Nantes, France
| | | | - A Toutain
- Service de Génétique, Centre Hospitalo-Universitaire, Tours, France
| | - S Arpin
- Service de Génétique, Centre Hospitalo-Universitaire, Tours, France
| | - S Blesson
- Service de Génétique, Centre Hospitalo-Universitaire, Tours, France
| | - I Mortemousque
- Service de Génétique, Centre Hospitalo-Universitaire, Tours, France
| | - E Schaefer
- Service de Génétique Médicale, Hôpital de Hautepierre, Strasbourg, France
| | - D Martin
- Service de Génétique Médicale, Hôpital du Mans, Le Mans, France
| | - N Philip
- Département de Génétique Médicale, Hôpital d'Enfants de La Timone, Marseille, France
| | - S Sigaudy
- Département de Génétique Médicale, Hôpital d'Enfants de La Timone, Marseille, France
| | - T Busa
- Département de Génétique Médicale, Hôpital d'Enfants de La Timone, Marseille, France
| | - C Missirian
- Département de Génétique Médicale, Hôpital d'Enfants de La Timone, Marseille, France
| | - F Giuliano
- Service de Génétique Médicale, Hôpital de l'Archet II, CHU de Nice, Nice, France
| | - H K Benailly
- Service de Génétique Médicale, Hôpital de l'Archet II, CHU de Nice, Nice, France
| | - P K V Kien
- Service de Génétique Médicale, Hôpital Caremeau, CHU de Nimes, Nimes, France
| | - B Leheup
- CHU de Nancy Pole Enfant, Centre de Référence Maladies Rares CLAD Est, Service de Médecine Infantile III et Génétique Clinique, Nancy, France
| | - C Benneteau
- CHU de Nancy Pole Enfant, Centre de Référence Maladies Rares CLAD Est, Service de Médecine Infantile III et Génétique Clinique, Nancy, France
| | - L Lambert
- CHU de Nancy Pole Enfant, Centre de Référence Maladies Rares CLAD Est, Service de Médecine Infantile III et Génétique Clinique, Nancy, France
| | - R Caumes
- APHP, Hôpital Robert Debré, Service de Neurologie Pédiatrique, Paris, France
| | - P Kuentz
- Service de génétique, Centre Hospitalier Universitaire de Besançon, Besançon, France
| | | | - D Heron
- Service de Génétique, APHP, Groupe Hospitalier de la Pitié-Salpétrière, Paris, France
| | - B Keren
- Service de Génétique, APHP, Groupe Hospitalier de la Pitié-Salpétrière, Paris, France
| | - E Cretin
- FHU-TRANSLAD, Université de Bourgogne, Dijon, France.,Espace Régional Éthique Bourgogne-Franche Comté, CHU, Besançon, France
| | - P Callier
- Centre de Génétique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs de l'Est, FHU-TRANSLAD, Dijon, France.,Génétique des Anomalies du Développement, Université de Bourgogne, Dijon, France.,FHU-TRANSLAD, Université de Bourgogne, Dijon, France
| | - S Julia
- Service de Génétique Médicale, Hôpital Purpan, CHU Toulouse, Université Paul Sabatier Toulouse, Toulouse, France
| | - L Faivre
- Centre de Génétique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs de l'Est, FHU-TRANSLAD, Dijon, France.,Génétique des Anomalies du Développement, Université de Bourgogne, Dijon, France.,FHU-TRANSLAD, Université de Bourgogne, Dijon, France
| |
Collapse
|
22
|
Mousty E, Issa S, Grosjean F, Col JY, Khau Van Kien P, Perez MJ, Petrov Y, Reboul D, Faubert E, Le Gac MP, Bondurand N, Chiesa J, Pingault V. A homozygous PAX3
mutation leading to severe presentation of Waardenburg syndrome with a prenatal diagnosis. Prenat Diagn 2015; 35:1379-81. [DOI: 10.1002/pd.4703] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2015] [Accepted: 10/03/2015] [Indexed: 11/06/2022]
Affiliation(s)
- Eve Mousty
- Gynécologie Obstétrique; CHRU Caremeau; Nimes France
| | - Sarah Issa
- INSERM, U955, Equipe 6; Créteil France
- Université Paris-Est, UMR_S955, UPEC; Créteil France
| | | | - Jean-Yves Col
- Gynécologie Obstétrique; Centre Hospitalier d'Avignon; Avignon France
| | | | - Marie-Josée Perez
- Département de Génétique Médicale; Hôpital Arnaud de Villeneuve; Montpellier France
| | - Yuliya Petrov
- Laboratoire de Cytogénétique et Génétique Médicale; CHRU Caremeau; Nimes France
| | - Dorothée Reboul
- Laboratoire de Cytogénétique et Génétique Médicale; CHRU Caremeau; Nimes France
| | | | | | - Nadège Bondurand
- INSERM, U955, Equipe 6; Créteil France
- Université Paris-Est, UMR_S955, UPEC; Créteil France
| | - Jean Chiesa
- Laboratoire de Cytogénétique et Génétique Médicale; CHRU Caremeau; Nimes France
| | - Véronique Pingault
- INSERM, U955, Equipe 6; Créteil France
- Université Paris-Est, UMR_S955, UPEC; Créteil France
- Hôpital Henri Mondor, AP-HP; Département de Génétique; Créteil France
| |
Collapse
|
23
|
Haine E, Salles JP, Khau Van Kien P, Conte-Auriol F, Gennero I, Plancke A, Julia S, Dulac Y, Tauber M, Edouard T. Muscle and Bone Impairment in Children With Marfan Syndrome: Correlation With Age and FBN1 Genotype. J Bone Miner Res 2015; 30:1369-76. [PMID: 25656438 DOI: 10.1002/jbmr.2471] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/18/2014] [Revised: 01/22/2015] [Accepted: 01/31/2015] [Indexed: 01/07/2023]
Abstract
Marfan syndrome (MFS) is a rare connective tissue disorder caused by mutation in the gene encoding the extracellular matrix protein fibrillin-1 (FBN1), leading to transforming growth factor-beta (TGF-β) signaling dysregulation. Although decreased axial and peripheral bone mineral density (BMD) has been reported in adults with MFS, data about the evolution of bone mass during childhood and adolescence are limited. The aim of the present study was to evaluate bone and muscle characteristics in children, adolescents, and young adults with MFS. The study population included 48 children and young adults (22 girls) with MFS with a median age of 11.9 years (range 5.3 to 25.2 years). The axial skeleton was analyzed at the lumbar spine using dual-energy X-ray absorptiometry (DXA), whereas the appendicular skeleton (hand) was evaluated using the BoneXpert system (with the calculation of the Bone Health Index). Muscle mass was measured by DXA. Compared with healthy age-matched controls, bone mass at the axial and appendicular levels and muscle mass were decreased in children with MFS and worsened from childhood to adulthood. Vitamin D deficiency (<50 nmol/L) was found in about a quarter of patients. Serum vitamin D levels were negatively correlated with age and positively correlated with lumbar spine areal and volumetric BMD. Lean body mass (LBM) Z-scores were positively associated with total body bone mineral content (TB-BMC) Z-scores, and LBM was an independent predictor of TB-BMC values, suggesting that muscle hypoplasia could explain at least in part the bone loss in MFS. Patients with a FBN1 premature termination codon mutation had a more severe musculoskeletal phenotype than patients with an inframe mutation, suggesting the involvement of TGF-β signaling dysregulation in the pathophysiologic mechanisms. In light of these results, we recommend that measurement of bone mineral status should be part of the longitudinal clinical investigation of MFS children.
Collapse
Affiliation(s)
- Elsa Haine
- Endocrine, Bone Diseases, and Genetics Unit, Children's Hospital, Toulouse University Hospital, Toulouse, France
| | - Jean-Pierre Salles
- Endocrine, Bone Diseases, and Genetics Unit, Children's Hospital, Toulouse University Hospital, Toulouse, France.,INSERM UMR 1043, Centre of Pathophysiology of Toulouse Purpan (CPTP), University of Toulouse Paul Sabatier, Toulouse, France
| | | | - Françoise Conte-Auriol
- INSERM UMR 1043, Centre of Pathophysiology of Toulouse Purpan (CPTP), University of Toulouse Paul Sabatier, Toulouse, France.,Pediatric Clinical Investigation Center, Children's Hospital, Toulouse University Hospital, Toulouse, France
| | - Isabelle Gennero
- INSERM UMR 1043, Centre of Pathophysiology of Toulouse Purpan (CPTP), University of Toulouse Paul Sabatier, Toulouse, France.,Biochemical Laboratory, Institut Fédératif de Biologie, Toulouse University Hospital, Toulouse, France
| | - Aurélie Plancke
- Medical Genetics Unit, Nîmes University Hospital, CHU Carémeau, Nîmes, France
| | - Sophie Julia
- Genetics Unit, Toulouse University Hospital, Toulouse, France
| | - Yves Dulac
- Cardiology Unit, Children's Hospital, Toulouse University Hospital, Toulouse, France
| | - Maithé Tauber
- Endocrine, Bone Diseases, and Genetics Unit, Children's Hospital, Toulouse University Hospital, Toulouse, France.,INSERM UMR 1043, Centre of Pathophysiology of Toulouse Purpan (CPTP), University of Toulouse Paul Sabatier, Toulouse, France
| | - Thomas Edouard
- Endocrine, Bone Diseases, and Genetics Unit, Children's Hospital, Toulouse University Hospital, Toulouse, France.,INSERM UMR 1043, Centre of Pathophysiology of Toulouse Purpan (CPTP), University of Toulouse Paul Sabatier, Toulouse, France
| |
Collapse
|
24
|
Monin ML, Mignot C, De Lonlay P, Héron B, Masurel A, Mathieu-Dramard M, Lenaerts C, Thauvin C, Gérard M, Roze E, Jacquette A, Charles P, de Baracé C, Drouin-Garraud V, Khau Van Kien P, Cormier-Daire V, Mayer M, Ogier H, Brice A, Seta N, Héron D. 29 French adult patients with PMM2-congenital disorder of glycosylation: outcome of the classical pediatric phenotype and depiction of a late-onset phenotype. Orphanet J Rare Dis 2014; 9:207. [PMID: 25497157 PMCID: PMC4266234 DOI: 10.1186/s13023-014-0207-4] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2014] [Accepted: 12/02/2014] [Indexed: 11/20/2022] Open
Abstract
PMM2-CDG (formerly known as CDG Ia) a deficiency in phosphomannomutase, is the most frequent congenital disorder of glycosylation. The phenotype encompasses a wide range of neurological and non-neurological manifestations comprising cerebellar atrophy and intellectual deficiency. The phenotype of the disorder is well characterized in children but the long term course of the disease is unknown and the phenotype of late onset forms has not been comprehensively described. We thus retrospectively collected the clinical, biological and radiological data of 29 French PMM2-CDG patients aged 15 years or more with a proven molecular diagnosis (16 females and 13 males). In addition, thirteen of these patients were reexamined at the time of the study to obtain detailed information. 27 of the 29 patients had a typical PMM2-CDG phenotype, with infantile hypotonia, strabismus, developmental delay followed by intellectual deficiency, epilepsy, retinitis pigmentosa and/or visceral manifestations. The main health problems for these patients as teenagers and in adulthood were primary ovarian insufficiency, growth retardation, coagulation anomalies and thrombotic events, skeletal deformities and osteopenia/osteoporosis, retinitis pigmentosa, as well as peripheral neuropathy. Three patients had never walked and three lost their ability to walk. The two remaining patients had a late-onset phenotype unreported to date. All patients (n = 29) had stable cerebellar atrophy. Our findings are in line with those of previous adult PMM2-CDG cohorts and points to the need for a multidisciplinary approach to the follow up of PMM2-CDG patients to prevent late complications. Additionally, our findings add weight to the view that PMM2-CDG may be diagnosed in teenage/adult patients with cerebellar atrophy, even in the absence of intellectual deficiency or non-neurological involvement.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Delphine Héron
- AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Département de Génétique, Unité Fonctionnelle de Neurogénétique moléculaire et cellulaire et Centre de Référence des Déficiences Intellectuelles de Causes Rares, 47-83 boulevard de l'hôpital, Paris, 75013, France.
| |
Collapse
|
25
|
Ishmukhametova A, Chen JM, Bernard R, de Massy B, Baudat F, Boyer A, Méchin D, Thorel D, Chabrol B, Vincent MC, Khau Van Kien P, Claustres M, Tuffery-Giraud S. Dissecting the Structure and Mechanism of a Complex Duplication-Triplication Rearrangement in theDMDGene. Hum Mutat 2013; 34:1080-4. [DOI: 10.1002/humu.22353] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2012] [Accepted: 04/27/2013] [Indexed: 01/21/2023]
Affiliation(s)
- Aliya Ishmukhametova
- Université Montpellier 1; UFR médecine; Montpellier F-34000 France
- CHU Montpellier, Hôpital Arnaud de Villeneuve; Laboratoire de Génétique Moléculaire; Montpellier F-34000 France
| | - Jian-Min Chen
- INSERM U1078 and Établissement Français du Sang (EFS) - Bretagne; Brest F-29218 France
| | - Rafaëlle Bernard
- Laboratoire de Génétique Moléculaire; Hôpital de la Timone CHU; Marseille F-13385 France
| | - Bernard de Massy
- Institut de Génétique Humaine; UPR1142, CNRS; Montpellier France
| | - Frédéric Baudat
- Institut de Génétique Humaine; UPR1142, CNRS; Montpellier France
| | - Amandine Boyer
- Laboratoire de Génétique Moléculaire; Hôpital de la Timone CHU; Marseille F-13385 France
| | - Déborah Méchin
- CHU Montpellier, Hôpital Arnaud de Villeneuve; Laboratoire de Génétique Moléculaire; Montpellier F-34000 France
| | - Delphine Thorel
- CHU Montpellier, Hôpital Arnaud de Villeneuve; Laboratoire de Génétique Moléculaire; Montpellier F-34000 France
| | - Brigitte Chabrol
- CHU La Timone; Service de Neurologie Pédiatrique; Marseille F-13385 France
| | - Marie-Claire Vincent
- CHU Montpellier, Hôpital Arnaud de Villeneuve; Laboratoire de Génétique Moléculaire; Montpellier F-34000 France
| | - Philippe Khau Van Kien
- CHU Montpellier, Hôpital Arnaud de Villeneuve; Laboratoire de Génétique Moléculaire; Montpellier F-34000 France
| | - Mireille Claustres
- Université Montpellier 1; UFR médecine; Montpellier F-34000 France
- CHU Montpellier, Hôpital Arnaud de Villeneuve; Laboratoire de Génétique Moléculaire; Montpellier F-34000 France
- INSERM, U827; Montpellier F-34000 France
| | - Sylvie Tuffery-Giraud
- Université Montpellier 1; UFR médecine; Montpellier F-34000 France
- INSERM, U827; Montpellier F-34000 France
| |
Collapse
|
26
|
Ishmukhametova A, Khau Van Kien P, Méchin D, Thorel D, Vincent MC, Rivier F, Coubes C, Humbertclaude V, Claustres M, Tuffery-Giraud S. Comprehensive oligonucleotide array-comparative genomic hybridization analysis: new insights into the molecular pathology of the DMD gene. Eur J Hum Genet 2012; 20:1096-100. [PMID: 22510846 DOI: 10.1038/ejhg.2012.51] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
We report on the effectiveness of a custom-designed oligonucleotide-based comparative genomic hybridization microarray (array-CGH) to interrogate copy number across the entire 2.2-Mb genomic region of the DMD gene and its applicability in diagnosis. The high-resolution array-CGH, we developed, successfully detected a series of 42 previously characterized large rearrangements of various size, localization and type (simple or complex deletions, duplications, triplications) and known intronic CNVs/Indels. Moreover, the technique succeeded in identifying a small duplication of only 191 bp in one patient previously negative for DMD mutation. Accurate intronic breakpoints localization by the technique enabled subsequent junction fragments identification by sequencing in 86% of cases (all deletion cases and 62.5% of duplication cases). Sequence examination of the junctions supports a role of microhomology-mediated processes in the occurrence of DMD large rearrangements. In addition, the precise knowledge of the sequence context at the breakpoints and analysis of the resulting consequences on maturation of pre-mRNA contribute to elucidating the cause of discrepancies in phenotype/genotype correlations in some patients. Thereby, the array-CGH proved to be a highly efficient and reliable diagnostic tool, and the new data it provides will have many potential implications in both, clinics and research.
Collapse
|
27
|
Khelifi MM, Ishmukhametova A, Khau Van Kien P, Thorel D, Méchin D, Perelman S, Pouget J, Claustres M, Tuffery-Giraud S. Pure intronic rearrangements leading to aberrant pseudoexon inclusion in dystrophinopathy: a new class of mutations? Hum Mutat 2011; 32:467-75. [PMID: 21305657 DOI: 10.1002/humu.21471] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2010] [Accepted: 01/20/2011] [Indexed: 12/12/2022]
Abstract
We report on two unprecedented cases of pseudoexon (PE) activation in the DMD gene resulting from pure intronic double-deletion events that possibly involve microhomology-mediated mechanisms. Array comparative genomic hybridization analysis and direct genomic sequencing allowed us to elucidate the causes of the pathological PE inclusion detected in the RNA of the patients. In the first case (Duchenne phenotype), we showed that the inserted 387-bp PE was originated from an inverted ∼57 kb genomic region of intron 44 flanked by two deleted ∼52 kb and ∼1 kb segments. In the second case (Becker phenotype), we identified in intron 56 two small deletions of 592 bp (del 1) and 29 bp (del 2) directly flanking a 166-bp PE located in very close proximity (134 bp) to exon 57. The key role of del 1 in PE activation was established by using splicing reporter minigenes. However, the analysis of mutant constructs failed to identify cis elements that regulate the inclusion of the PE and suggested that other splicing regulatory factors may be involved such as RNA structure. Our study introduces a new class of mutations in the DMD gene and emphasizes the potential role of underdetected intronic rearrangements in human diseases.
Collapse
|
28
|
Faivre L, Van Kien PK, Callier P, Ruiz-Pallares N, Baudoin C, Plancke A, Wolf JE, Thauvin-Robinet C, Durand E, Minot D, Dulieu V, Metaizeau JD, Leheup B, Coron F, Bidot S, Huet F, Jondeau G, Boileau C, Claustres M, Mugneret F. De novo 15q21.1q21.2 deletion identified through FBN1 MLPA and refined by 244K array-CGH in a female teenager with incomplete Marfan syndrome. Eur J Med Genet 2010; 53:208-12. [DOI: 10.1016/j.ejmg.2010.05.002] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2010] [Accepted: 05/04/2010] [Indexed: 10/19/2022]
|
29
|
Barat-Houari M, Nguyen K, Bernard R, Fernandez C, Vovan C, Bareil C, Khau Van Kien P, Thorel D, Tuffery-Giraud S, Vasseur F, Attarian S, Pouget J, Girardet A, Lévy N, Claustres M. New multiplex PCR-based protocol allowing indirect diagnosis of FSHD on single cells: can PGD be offered despite high risk of recombination? Eur J Hum Genet 2010; 18:533-8. [PMID: 19935833 PMCID: PMC2987324 DOI: 10.1038/ejhg.2009.207] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2009] [Revised: 10/01/2009] [Accepted: 10/14/2009] [Indexed: 01/23/2023] Open
Abstract
Molecular pathophysiology of facioscapulohumeral muscular dystrophy (FSHD) involves the heterozygous contraction of the number of tandemly repeated D4Z4 units at chromosome 4q35.2. FSHD is associated with a range of 1-10 D4Z4 units instead of 11-150 in normal controls. Several factors complicate FSHD molecular diagnosis, especially the cis-segregation of D4Z4 contraction with a 4qA allele, whereas D4Z4 shortening is silent both on alleles 4qB and 10q. Discrimination of pathogenic 4q-D4Z4 alleles from highly homologous 10q-D4Z4 arrays requires the use of the conventional Southern blot, which is not suitable at the single-cell level. Preimplantation genetic diagnosis (PGD) is a frequent request from FSHD families with several affected relatives. We aimed to develop a rapid and sensitive PCR-based multiplex approach on single cells to perform an indirect familial segregation study of pathogenic alleles. Among several available polymorphic markers at 4q35.2, the four most proximal (D4S2390, D4S1652, D4S2930 and D4S1523, <1.23 Mb) showing the highest heterozygote frequencies (67-91%) were selected. Five recombination events in the D4S2390-D4S1523 interval were observed among 144 meioses. In the D4S2390-D4Z4 interval, no recombination event occurred among 28 FSHD meioses. Instead, a particular haplotype segregated with both clinical and molecular status, allowing the characterization of an at-risk allele in each tested FSHD family (maximal LOD score 2.98 for theta=0.0). This indirect protocol can easily complement conventional techniques in prenatal diagnosis. Although our multiplex PCR-based approach technically fulfils guidelines for single-cell analysis, the relatively high recombination risk hampers its application to PGD.
Collapse
Affiliation(s)
- Mouna Barat-Houari
- CHU de Montpellier, Laboratoire de Génétique Moléculaire, Montpellier, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Khau Van Kien P. Les tests diagnostiques dans les maladies rares : évolutions technologiques nécessaires. Presse Med 2010. [DOI: 10.1016/j.lpm.2010.02.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
31
|
Van Kien PK, Baux D, Pallares-Ruiz N, Baudoin C, Plancke A, Chassaing N, Collignon P, Drouin-Garraud V, Hovnanian A, Martin-Coignard D, Collod-Béroud G, Béroud C, Roux AF, Claustres M. Missense mutations of conserved glycine residues in fibrillin-1 highlight a potential subtype of cb-EGF-like domains. Hum Mutat 2010; 31:E1021-42. [DOI: 10.1002/humu.21131] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
32
|
Attias D, Stheneur C, Roy C, Collod-Béroud G, Detaint D, Faivre L, Delrue MA, Cohen L, Francannet C, Béroud C, Claustres M, Iserin F, Khau Van Kien P, Lacombe D, Le Merrer M, Lyonnet S, Odent S, Plauchu H, Rio M, Rossi A, Sidi D, Steg PG, Ravaud P, Boileau C, Jondeau G. Comparison of Clinical Presentations and Outcomes Between Patients With
TGFBR2
and
FBN1
Mutations in Marfan Syndrome and Related Disorders. Circulation 2009; 120:2541-9. [DOI: 10.1161/circulationaha.109.887042] [Citation(s) in RCA: 162] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Background—
TGFBR2
mutations were recognized recently among patients with a Marfan-like phenotype. The associated clinical and prognostic spectra remain unclear.
Methods and Results—
Clinical features and outcomes of 71 patients with a
TGFBR2
mutation (TGFBR2 group) were compared with 50 age- and sex-matched unaffected family members (control subjects) and 243 patients harboring
FBN1
mutations (FBN1 group). Aortic dilatation was present in a similar proportion of patients in both the TGFBR2 and FBN1 groups (78% versus 79%, respectively) but was highly variable. The incidence and average age for thoracic aortic surgery (31% versus 27% and 35±16 versus 39±13 years, respectively) and aortic dissection (14% versus 10% and 38±12 versus 39±9 years) were also similar in the 2 groups. Mitral valve involvement (myxomatous, prolapse, mitral regurgitation) was less frequent in the TGFBR2 than in the FBN1 group (all
P
<0.05). Aortic dilatation, dissection, or sudden death was the index event leading to genetic diagnosis in 65% of families with
TGFBR2
mutations, versus 32% with
FBN1
mutations (
P
=0.002). The rate of death was greater in TGFBR2 families before diagnosis but similar once the disease had been recognized. Most pregnancies were uneventful (without death or aortic dissection) in both TGFBR2 and FBN1 families (38 of 39 versus 213 of 217;
P
=1). Seven patients (10%) with a
TGFBR2
mutation fulfilled international criteria for Marfan syndrome, 3 of whom presented with features specific for Loeys-Dietz syndrome.
Conclusions—
Clinical outcomes appear similar between treated patients with
TGFBR2
mutations and individuals with
FBN1
mutations. Prognosis depends on clinical disease expression and treatment rather than simply the presence of a
TGFBR2
gene mutation.
Collapse
Affiliation(s)
- David Attias
- From AP-HP, Hôpital Bichat, Consultation Multidisciplinaire Marfan, Paris (D.A., C.S., D.D., C. Boileau, G.J.); AP-HP, Hôpital Bichat, Service de Cardiologie, and Université Denis Diderot Paris VII, Paris (D.A., D.D., P.G.S., G.J.); INSERM, U781, Paris (C.S.); AP-HP, Hôpital A. Pare, Service de Pédiatrie, and Université Versailles-SQY, Boulogne (C.S.); AP-HP, Hôpital Bichat, Biostatistique et Recherche Clinique, and INSERM, U738, Paris (C.R., P.R.); INSERM, U827, and Université Montpellier1,
| | - Chantal Stheneur
- From AP-HP, Hôpital Bichat, Consultation Multidisciplinaire Marfan, Paris (D.A., C.S., D.D., C. Boileau, G.J.); AP-HP, Hôpital Bichat, Service de Cardiologie, and Université Denis Diderot Paris VII, Paris (D.A., D.D., P.G.S., G.J.); INSERM, U781, Paris (C.S.); AP-HP, Hôpital A. Pare, Service de Pédiatrie, and Université Versailles-SQY, Boulogne (C.S.); AP-HP, Hôpital Bichat, Biostatistique et Recherche Clinique, and INSERM, U738, Paris (C.R., P.R.); INSERM, U827, and Université Montpellier1,
| | - Carine Roy
- From AP-HP, Hôpital Bichat, Consultation Multidisciplinaire Marfan, Paris (D.A., C.S., D.D., C. Boileau, G.J.); AP-HP, Hôpital Bichat, Service de Cardiologie, and Université Denis Diderot Paris VII, Paris (D.A., D.D., P.G.S., G.J.); INSERM, U781, Paris (C.S.); AP-HP, Hôpital A. Pare, Service de Pédiatrie, and Université Versailles-SQY, Boulogne (C.S.); AP-HP, Hôpital Bichat, Biostatistique et Recherche Clinique, and INSERM, U738, Paris (C.R., P.R.); INSERM, U827, and Université Montpellier1,
| | - Gwenaëlle Collod-Béroud
- From AP-HP, Hôpital Bichat, Consultation Multidisciplinaire Marfan, Paris (D.A., C.S., D.D., C. Boileau, G.J.); AP-HP, Hôpital Bichat, Service de Cardiologie, and Université Denis Diderot Paris VII, Paris (D.A., D.D., P.G.S., G.J.); INSERM, U781, Paris (C.S.); AP-HP, Hôpital A. Pare, Service de Pédiatrie, and Université Versailles-SQY, Boulogne (C.S.); AP-HP, Hôpital Bichat, Biostatistique et Recherche Clinique, and INSERM, U738, Paris (C.R., P.R.); INSERM, U827, and Université Montpellier1,
| | - Delphine Detaint
- From AP-HP, Hôpital Bichat, Consultation Multidisciplinaire Marfan, Paris (D.A., C.S., D.D., C. Boileau, G.J.); AP-HP, Hôpital Bichat, Service de Cardiologie, and Université Denis Diderot Paris VII, Paris (D.A., D.D., P.G.S., G.J.); INSERM, U781, Paris (C.S.); AP-HP, Hôpital A. Pare, Service de Pédiatrie, and Université Versailles-SQY, Boulogne (C.S.); AP-HP, Hôpital Bichat, Biostatistique et Recherche Clinique, and INSERM, U738, Paris (C.R., P.R.); INSERM, U827, and Université Montpellier1,
| | - Laurence Faivre
- From AP-HP, Hôpital Bichat, Consultation Multidisciplinaire Marfan, Paris (D.A., C.S., D.D., C. Boileau, G.J.); AP-HP, Hôpital Bichat, Service de Cardiologie, and Université Denis Diderot Paris VII, Paris (D.A., D.D., P.G.S., G.J.); INSERM, U781, Paris (C.S.); AP-HP, Hôpital A. Pare, Service de Pédiatrie, and Université Versailles-SQY, Boulogne (C.S.); AP-HP, Hôpital Bichat, Biostatistique et Recherche Clinique, and INSERM, U738, Paris (C.R., P.R.); INSERM, U827, and Université Montpellier1,
| | - Marie-Ange Delrue
- From AP-HP, Hôpital Bichat, Consultation Multidisciplinaire Marfan, Paris (D.A., C.S., D.D., C. Boileau, G.J.); AP-HP, Hôpital Bichat, Service de Cardiologie, and Université Denis Diderot Paris VII, Paris (D.A., D.D., P.G.S., G.J.); INSERM, U781, Paris (C.S.); AP-HP, Hôpital A. Pare, Service de Pédiatrie, and Université Versailles-SQY, Boulogne (C.S.); AP-HP, Hôpital Bichat, Biostatistique et Recherche Clinique, and INSERM, U738, Paris (C.R., P.R.); INSERM, U827, and Université Montpellier1,
| | - Laurence Cohen
- From AP-HP, Hôpital Bichat, Consultation Multidisciplinaire Marfan, Paris (D.A., C.S., D.D., C. Boileau, G.J.); AP-HP, Hôpital Bichat, Service de Cardiologie, and Université Denis Diderot Paris VII, Paris (D.A., D.D., P.G.S., G.J.); INSERM, U781, Paris (C.S.); AP-HP, Hôpital A. Pare, Service de Pédiatrie, and Université Versailles-SQY, Boulogne (C.S.); AP-HP, Hôpital Bichat, Biostatistique et Recherche Clinique, and INSERM, U738, Paris (C.R., P.R.); INSERM, U827, and Université Montpellier1,
| | - Christine Francannet
- From AP-HP, Hôpital Bichat, Consultation Multidisciplinaire Marfan, Paris (D.A., C.S., D.D., C. Boileau, G.J.); AP-HP, Hôpital Bichat, Service de Cardiologie, and Université Denis Diderot Paris VII, Paris (D.A., D.D., P.G.S., G.J.); INSERM, U781, Paris (C.S.); AP-HP, Hôpital A. Pare, Service de Pédiatrie, and Université Versailles-SQY, Boulogne (C.S.); AP-HP, Hôpital Bichat, Biostatistique et Recherche Clinique, and INSERM, U738, Paris (C.R., P.R.); INSERM, U827, and Université Montpellier1,
| | - Christophe Béroud
- From AP-HP, Hôpital Bichat, Consultation Multidisciplinaire Marfan, Paris (D.A., C.S., D.D., C. Boileau, G.J.); AP-HP, Hôpital Bichat, Service de Cardiologie, and Université Denis Diderot Paris VII, Paris (D.A., D.D., P.G.S., G.J.); INSERM, U781, Paris (C.S.); AP-HP, Hôpital A. Pare, Service de Pédiatrie, and Université Versailles-SQY, Boulogne (C.S.); AP-HP, Hôpital Bichat, Biostatistique et Recherche Clinique, and INSERM, U738, Paris (C.R., P.R.); INSERM, U827, and Université Montpellier1,
| | - Mireille Claustres
- From AP-HP, Hôpital Bichat, Consultation Multidisciplinaire Marfan, Paris (D.A., C.S., D.D., C. Boileau, G.J.); AP-HP, Hôpital Bichat, Service de Cardiologie, and Université Denis Diderot Paris VII, Paris (D.A., D.D., P.G.S., G.J.); INSERM, U781, Paris (C.S.); AP-HP, Hôpital A. Pare, Service de Pédiatrie, and Université Versailles-SQY, Boulogne (C.S.); AP-HP, Hôpital Bichat, Biostatistique et Recherche Clinique, and INSERM, U738, Paris (C.R., P.R.); INSERM, U827, and Université Montpellier1,
| | - Franck Iserin
- From AP-HP, Hôpital Bichat, Consultation Multidisciplinaire Marfan, Paris (D.A., C.S., D.D., C. Boileau, G.J.); AP-HP, Hôpital Bichat, Service de Cardiologie, and Université Denis Diderot Paris VII, Paris (D.A., D.D., P.G.S., G.J.); INSERM, U781, Paris (C.S.); AP-HP, Hôpital A. Pare, Service de Pédiatrie, and Université Versailles-SQY, Boulogne (C.S.); AP-HP, Hôpital Bichat, Biostatistique et Recherche Clinique, and INSERM, U738, Paris (C.R., P.R.); INSERM, U827, and Université Montpellier1,
| | - Philippe Khau Van Kien
- From AP-HP, Hôpital Bichat, Consultation Multidisciplinaire Marfan, Paris (D.A., C.S., D.D., C. Boileau, G.J.); AP-HP, Hôpital Bichat, Service de Cardiologie, and Université Denis Diderot Paris VII, Paris (D.A., D.D., P.G.S., G.J.); INSERM, U781, Paris (C.S.); AP-HP, Hôpital A. Pare, Service de Pédiatrie, and Université Versailles-SQY, Boulogne (C.S.); AP-HP, Hôpital Bichat, Biostatistique et Recherche Clinique, and INSERM, U738, Paris (C.R., P.R.); INSERM, U827, and Université Montpellier1,
| | - Didier Lacombe
- From AP-HP, Hôpital Bichat, Consultation Multidisciplinaire Marfan, Paris (D.A., C.S., D.D., C. Boileau, G.J.); AP-HP, Hôpital Bichat, Service de Cardiologie, and Université Denis Diderot Paris VII, Paris (D.A., D.D., P.G.S., G.J.); INSERM, U781, Paris (C.S.); AP-HP, Hôpital A. Pare, Service de Pédiatrie, and Université Versailles-SQY, Boulogne (C.S.); AP-HP, Hôpital Bichat, Biostatistique et Recherche Clinique, and INSERM, U738, Paris (C.R., P.R.); INSERM, U827, and Université Montpellier1,
| | - Martine Le Merrer
- From AP-HP, Hôpital Bichat, Consultation Multidisciplinaire Marfan, Paris (D.A., C.S., D.D., C. Boileau, G.J.); AP-HP, Hôpital Bichat, Service de Cardiologie, and Université Denis Diderot Paris VII, Paris (D.A., D.D., P.G.S., G.J.); INSERM, U781, Paris (C.S.); AP-HP, Hôpital A. Pare, Service de Pédiatrie, and Université Versailles-SQY, Boulogne (C.S.); AP-HP, Hôpital Bichat, Biostatistique et Recherche Clinique, and INSERM, U738, Paris (C.R., P.R.); INSERM, U827, and Université Montpellier1,
| | - Stanislas Lyonnet
- From AP-HP, Hôpital Bichat, Consultation Multidisciplinaire Marfan, Paris (D.A., C.S., D.D., C. Boileau, G.J.); AP-HP, Hôpital Bichat, Service de Cardiologie, and Université Denis Diderot Paris VII, Paris (D.A., D.D., P.G.S., G.J.); INSERM, U781, Paris (C.S.); AP-HP, Hôpital A. Pare, Service de Pédiatrie, and Université Versailles-SQY, Boulogne (C.S.); AP-HP, Hôpital Bichat, Biostatistique et Recherche Clinique, and INSERM, U738, Paris (C.R., P.R.); INSERM, U827, and Université Montpellier1,
| | - Sylvie Odent
- From AP-HP, Hôpital Bichat, Consultation Multidisciplinaire Marfan, Paris (D.A., C.S., D.D., C. Boileau, G.J.); AP-HP, Hôpital Bichat, Service de Cardiologie, and Université Denis Diderot Paris VII, Paris (D.A., D.D., P.G.S., G.J.); INSERM, U781, Paris (C.S.); AP-HP, Hôpital A. Pare, Service de Pédiatrie, and Université Versailles-SQY, Boulogne (C.S.); AP-HP, Hôpital Bichat, Biostatistique et Recherche Clinique, and INSERM, U738, Paris (C.R., P.R.); INSERM, U827, and Université Montpellier1,
| | - Henri Plauchu
- From AP-HP, Hôpital Bichat, Consultation Multidisciplinaire Marfan, Paris (D.A., C.S., D.D., C. Boileau, G.J.); AP-HP, Hôpital Bichat, Service de Cardiologie, and Université Denis Diderot Paris VII, Paris (D.A., D.D., P.G.S., G.J.); INSERM, U781, Paris (C.S.); AP-HP, Hôpital A. Pare, Service de Pédiatrie, and Université Versailles-SQY, Boulogne (C.S.); AP-HP, Hôpital Bichat, Biostatistique et Recherche Clinique, and INSERM, U738, Paris (C.R., P.R.); INSERM, U827, and Université Montpellier1,
| | - Marlène Rio
- From AP-HP, Hôpital Bichat, Consultation Multidisciplinaire Marfan, Paris (D.A., C.S., D.D., C. Boileau, G.J.); AP-HP, Hôpital Bichat, Service de Cardiologie, and Université Denis Diderot Paris VII, Paris (D.A., D.D., P.G.S., G.J.); INSERM, U781, Paris (C.S.); AP-HP, Hôpital A. Pare, Service de Pédiatrie, and Université Versailles-SQY, Boulogne (C.S.); AP-HP, Hôpital Bichat, Biostatistique et Recherche Clinique, and INSERM, U738, Paris (C.R., P.R.); INSERM, U827, and Université Montpellier1,
| | - Annick Rossi
- From AP-HP, Hôpital Bichat, Consultation Multidisciplinaire Marfan, Paris (D.A., C.S., D.D., C. Boileau, G.J.); AP-HP, Hôpital Bichat, Service de Cardiologie, and Université Denis Diderot Paris VII, Paris (D.A., D.D., P.G.S., G.J.); INSERM, U781, Paris (C.S.); AP-HP, Hôpital A. Pare, Service de Pédiatrie, and Université Versailles-SQY, Boulogne (C.S.); AP-HP, Hôpital Bichat, Biostatistique et Recherche Clinique, and INSERM, U738, Paris (C.R., P.R.); INSERM, U827, and Université Montpellier1,
| | - Daniel Sidi
- From AP-HP, Hôpital Bichat, Consultation Multidisciplinaire Marfan, Paris (D.A., C.S., D.D., C. Boileau, G.J.); AP-HP, Hôpital Bichat, Service de Cardiologie, and Université Denis Diderot Paris VII, Paris (D.A., D.D., P.G.S., G.J.); INSERM, U781, Paris (C.S.); AP-HP, Hôpital A. Pare, Service de Pédiatrie, and Université Versailles-SQY, Boulogne (C.S.); AP-HP, Hôpital Bichat, Biostatistique et Recherche Clinique, and INSERM, U738, Paris (C.R., P.R.); INSERM, U827, and Université Montpellier1,
| | - Philippe Gabriel Steg
- From AP-HP, Hôpital Bichat, Consultation Multidisciplinaire Marfan, Paris (D.A., C.S., D.D., C. Boileau, G.J.); AP-HP, Hôpital Bichat, Service de Cardiologie, and Université Denis Diderot Paris VII, Paris (D.A., D.D., P.G.S., G.J.); INSERM, U781, Paris (C.S.); AP-HP, Hôpital A. Pare, Service de Pédiatrie, and Université Versailles-SQY, Boulogne (C.S.); AP-HP, Hôpital Bichat, Biostatistique et Recherche Clinique, and INSERM, U738, Paris (C.R., P.R.); INSERM, U827, and Université Montpellier1,
| | - Philippe Ravaud
- From AP-HP, Hôpital Bichat, Consultation Multidisciplinaire Marfan, Paris (D.A., C.S., D.D., C. Boileau, G.J.); AP-HP, Hôpital Bichat, Service de Cardiologie, and Université Denis Diderot Paris VII, Paris (D.A., D.D., P.G.S., G.J.); INSERM, U781, Paris (C.S.); AP-HP, Hôpital A. Pare, Service de Pédiatrie, and Université Versailles-SQY, Boulogne (C.S.); AP-HP, Hôpital Bichat, Biostatistique et Recherche Clinique, and INSERM, U738, Paris (C.R., P.R.); INSERM, U827, and Université Montpellier1,
| | - Catherine Boileau
- From AP-HP, Hôpital Bichat, Consultation Multidisciplinaire Marfan, Paris (D.A., C.S., D.D., C. Boileau, G.J.); AP-HP, Hôpital Bichat, Service de Cardiologie, and Université Denis Diderot Paris VII, Paris (D.A., D.D., P.G.S., G.J.); INSERM, U781, Paris (C.S.); AP-HP, Hôpital A. Pare, Service de Pédiatrie, and Université Versailles-SQY, Boulogne (C.S.); AP-HP, Hôpital Bichat, Biostatistique et Recherche Clinique, and INSERM, U738, Paris (C.R., P.R.); INSERM, U827, and Université Montpellier1,
| | - Guillaume Jondeau
- From AP-HP, Hôpital Bichat, Consultation Multidisciplinaire Marfan, Paris (D.A., C.S., D.D., C. Boileau, G.J.); AP-HP, Hôpital Bichat, Service de Cardiologie, and Université Denis Diderot Paris VII, Paris (D.A., D.D., P.G.S., G.J.); INSERM, U781, Paris (C.S.); AP-HP, Hôpital A. Pare, Service de Pédiatrie, and Université Versailles-SQY, Boulogne (C.S.); AP-HP, Hôpital Bichat, Biostatistique et Recherche Clinique, and INSERM, U738, Paris (C.R., P.R.); INSERM, U827, and Université Montpellier1,
| |
Collapse
|
33
|
Tuffery-Giraud S, Béroud C, Leturcq F, Yaou RB, Hamroun D, Michel-Calemard L, Moizard MP, Bernard R, Cossée M, Boisseau P, Blayau M, Creveaux I, Guiochon-Mantel A, de Martinville B, Philippe C, Monnier N, Bieth E, Khau Van Kien P, Desmet FO, Humbertclaude V, Kaplan JC, Chelly J, Claustres M. Genotype-phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD-DMD database: a model of nationwide knowledgebase. Hum Mutat 2009; 30:934-45. [PMID: 19367636 DOI: 10.1002/humu.20976] [Citation(s) in RCA: 253] [Impact Index Per Article: 16.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
UMD-DMD France is a knowledgebase developed through a multicenter academic effort to provide an up-to-date resource of curated information covering all identified mutations in patients with a dystrophinopathy. The current release includes 2,411 entries consisting in 2,084 independent mutational events identified in 2,046 male patients and 38 expressing females, which corresponds to an estimated number of 39 people per million with a genetic diagnosis of dystrophinopathy in France. Mutations consist in 1,404 large deletions, 215 large duplications, and 465 small rearrangements, of which 39.8% are nonsense mutations. The reading frame rule holds true for 96% of the DMD patients and 93% of the BMD patients. Quality control relies on the curation by four experts for the DMD gene and related diseases. Data on dystrophin and RNA analysis, phenotypic groups, and transmission are also available. About 24% of the mutations are de novo events. This national centralized resource will contribute to a greater understanding of prevalence of dystrophinopathies in France, and in particular, of the true frequency of BMD, which was found to be almost half (43%) that of DMD. UMD-DMD is a searchable anonymous database that includes numerous newly developed tools, which can benefit to all the scientific community interested in dystrophinopathies. Dedicated functions for genotype-based therapies allowed the prediction of a new multiexon skipping (del 45-53) potentially applicable to 53% of the deleted DMD patients. Finally, such a national database will prove to be useful to implement the international global DMD patients' registries under development.
Collapse
|
34
|
Plancke A, Holder-Espinasse M, Rigau V, Manouvrier S, Claustres M, Khau Van Kien P. Homozygosity for a null allele of COL3A1 results in recessive Ehlers-Danlos syndrome. Eur J Hum Genet 2009; 17:1411-6. [PMID: 19455184 DOI: 10.1038/ejhg.2009.76] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
So far, mutations in the human COL3A1 gene have been associated with the predominantly inherited Ehlers-Danlos syndrome (EDS), vascular type. Genotype-phenotype correlation perspectives collapsed, as haploinsufficiency, which was long suggested to confer a milder or unrecognized phenotype, was reported in four patients with a phenotype similar to that of vascular EDS. Here, we study a case of recessive EDS in a young consanguineous girl of healthy parents. She fulfilled the vascular EDS criteria for laboratory testing. Total sequencing of COL3A1 cDNA identified a homozygous nucleotide duplication (c.479dupT) resulting in a premature termination codon (p.Lys161GlnfsX45). Studies in genomic DNA showed that this mutation was inherited from each parent. The expression analysis (RT-PCR, quantitative-PCR, immunohistochemistry, WB) showed strong mRNA decay and an absence of type III collagen in the proband. The expected COL3A1 haploinsufficiency in her healthy ascendants did not lead to the manifestations of vascular EDS. This case provides evidence of a stochastic effect of COL3A1 haploinsufficiency in humans, which could be explained by the relation between nonsense-mediated mRNA decay efficiency and the resulting dominant-negative effect depending on the position of the mutation and/or modifying factors. It opens up new perspectives for the understanding of COL3A1 genotype-phenotype correlations, which is required while considering targeted therapy.
Collapse
|
35
|
Giansily-Blaizot M, Thorel D, Khau Van Kien P, Behar C, Romey MC, Mugneret F, Schved JF, Claustres M. Characterisation of a large complex intragenic re-arrangement in the FVII gene (F7) avoiding misdiagnosis in inherited factor VII deficiency. Br J Haematol 2007; 138:359-65. [PMID: 17614823 DOI: 10.1111/j.1365-2141.2007.06660.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Inherited factor VII (FVII) deficiency is a rare autosomal recessive bleeding disorder mostly caused by point mutations. Large genomic re-arrangements at F7 locus could account for a fraction of mutant alleles that remain unidentified after DNA sequencing, because they escape conventional polymerase chain reaction (PCR)-based techniques. We report the first systematic screening of F7 for large re-arrangements, by semi-quantitative multiplex PCR of fluorescent fragments targeting the 9 exons and the promoter region. A well-characterised cohort of 43 unrelated patients either apparently homozygous for a F7 point mutation or carrying at least one unidentified F7 mutant allele participated in this study. Two large F7 re-arrangements were identified in two FVII-deficient pedigrees, including a discontinuous deletion involving two distinct portions of F7 whose proximal and distal end junctions were characterised. A simple and efficient method for the routine detection of gross alterations of F7, which accounted for 2.3% of mutant alleles in our sample, is now available in inherited FVII deficiency. This test should complement conventional PCR-based techniques not only in unsolved cases, but also where inheritance pattern analysis is not achievable.
Collapse
Affiliation(s)
- Muriel Giansily-Blaizot
- Inserm, U827, Laboratoire de Génétique de Maladies Rares: Pathologie Moléculaire, Etudes Fonctionnelles et Banques de Données Génétiques, Montpellier, France.
| | | | | | | | | | | | | | | |
Collapse
|
36
|
Perdu J, Boutouyrie P, Lahlou-Laforêt K, Khau Van Kien P, Denarié N, Mousseaux E, Sapoval M, Julia P, Zinzindohoué F, Touraine P, Dumez Y, Trystram D, Vignal-Clermont C, Gimenez-Roqueplo AP, Jeunemaitre X, Fiessinger JN. Syndrome d’Ehlers-Danlos vasculaire. Presse Med 2006; 35:1864-75. [PMID: 17159712 DOI: 10.1016/s0755-4982(06)74919-3] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
The vascular type of Ehlers-Danlos syndrome (EDS) is a rare genetic disease transmitted as an autosomal dominant trait. It is distinguished from other forms of EDS by its unstable acrogeric morphotype and by vascular, gastrointestinal, and obstetrical complications. Diagnosis is based on various clinical signs, noninvasive imaging, and on the identification of a mutation of the COL3A1 gene, which provides diagnostic certainty but has a sensitivity of only 61%. When two major diagnostic criteria are present, a genetic test should be proposed, performed and its result presented in a multidisciplinary group. The precautionary principle requires that preventive measures be implemented when the diagnosis is suspected. All artery puncture, surgery, and gastrointestinal and uterine endoscopy are contraindicated, permissible only in life-threatening emergencies. Straining against a closed glottis and all other situations or drugs likely to raise blood pressure must be avoided. Contraception must be discussed to avoid pregnancy during the diagnostic period. Arterial lesions suggestive of the disease include dissecting aneurysms of the internal carotid and iliac arteries and of the anterior visceral branches of the abdominal aorta, fusiform aneurysms of the splenic artery, and early onset nontraumatic direct carotid-cavernous fistulae. Early-onset varicose veins, spontaneous peritonitis or unusually important perineal lesions after giving birth should also attract the physician's attention. Psychological treatment and support of patients and their families is essential, to help them both to live with their disease and to deal with the information and screening issues. The prognosis of Ehlers-Danlos syndrome, vascular type, is grim but there is wide interindividual variability and life expectancy is best among patients receiving regular follow-up. Management by an experienced multidisciplinary team, implementation of drastic prevention measures and, depending on the results of the BBEST study, the possible prescription of beta-blockers should help to reduce the risk of complications and justify hope for a real improvement in prognosis in the near future.
Collapse
Affiliation(s)
- Jérôme Perdu
- Groupe Multidisciplinaire de Prise en Charge du Syndrome d'Ehlers-Danlos Vasculaire, Hôpital européen Georges Pompidou, Paris.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Zhu L, Vranckx R, Khau Van Kien P, Lalande A, Boisset N, Mathieu F, Wegman M, Glancy L, Gasc JM, Brunotte F, Bruneval P, Wolf JE, Michel JB, Jeunemaitre X. Mutations in myosin heavy chain 11 cause a syndrome associating thoracic aortic aneurysm/aortic dissection and patent ductus arteriosus. Nat Genet 2006; 38:343-9. [PMID: 16444274 DOI: 10.1038/ng1721] [Citation(s) in RCA: 413] [Impact Index Per Article: 22.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2005] [Accepted: 10/31/2005] [Indexed: 11/08/2022]
Abstract
We have recently described two kindreds presenting thoracic aortic aneurysm and/or aortic dissection (TAAD) and patent ductus arteriosus (PDA) and mapped the disease locus to 16p12.2-p13.13 (ref. 3). We now demonstrate that the disease is caused by mutations in the MYH11 gene affecting the C-terminal coiled-coil region of the smooth muscle myosin heavy chain, a specific contractile protein of smooth muscle cells (SMC). All individuals bearing the heterozygous mutations, even if asymptomatic, showed marked aortic stiffness. Examination of pathological aortas showed large areas of medial degeneration with very low SMC content. Abnormal immunological recognition of SM-MHC and the colocalization of wild-type and mutant rod proteins in SMC, in conjunction with differences in their coimmunoprecipitation capacities, strongly suggest a dominant-negative effect. Human MYH11 gene mutations provide the first example of a direct change in a specific SMC protein leading to an inherited arterial disease.
Collapse
Affiliation(s)
- Limin Zhu
- Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Département de Génétique, 75015 Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Khau Van Kien P, Mathieu F, Zhu L, Lalande A, Betard C, Lathrop M, Brunotte F, Wolf JE, Jeunemaitre X. Mapping of familial thoracic aortic aneurysm/dissection with patent ductus arteriosus to 16p12.2-p13.13. Circulation 2005; 112:200-6. [PMID: 15998682 DOI: 10.1161/circulationaha.104.506345] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Three loci have been shown to be responsible for nonsyndromic familial thoracic aortic aneurysms (TAAs) and aortic dissections (ADs). We recently described a large family in which TAA/AD associates with patent ductus arteriosus (PDA) and provided genetic arguments for a unique pathophysiological entity. METHODS AND RESULTS Genome-wide scan was performed in 40 subjects belonging to 3 generations in this large pedigree. Using the 7 TAA/AD cases as affected, we observed positive 2-point LOD scores on adjacent markers at chromosome 16p, with a maximum LOD score value of 2.73 at theta=0, a value that increased to 3.56 when 5 PDA cases were included. Multipoint linkage analysis yielded a maximum LOD score of 4.14 in the vicinity of marker D16S3103. Fine mapping allowed the observation of recombinant haplotypes that delimited a critical 20-cM interval at 16p12.2-p13.13. Automatic determination of aortic compliance with cine MRI showed that all subjects bearing the disease haplotype, even asymptomatic, displayed a very low level of aortic compliance and distensibility. Aortic stiffness was strongly associated with disease haplotype with a marked effect of age, indicating subclinical and early manifestation of the disease. CONCLUSIONS Genetic analysis of this family identified a unique locus responsible for both TAA/AD and PDA at chromosome 16p12.2-p13.13 with aortic stiffness as an early hallmark of the disease. TAA/AD with PDA is a new monogenic entity among the genetically heterogeneous group of TAA/AD disease.
Collapse
|
39
|
Faivre L, Rousseau T, Laurent N, Gosset P, Sanlaville D, Thauvin-Robinet C, Cusin V, Lionnais S, Callier P, Khau Van Kien P, Huet F, Turleau C, Sagot P, Mugneret F. Prenatal overgrowth and mosaic trisomy 15q25-qter including the IGF1 receptor gene. Prenat Diagn 2004; 24:393-5. [PMID: 15164417 DOI: 10.1002/pd.891] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Overgrowth is rarely associated with chromosomal imbalances. Here, we report on a male foetus presenting with overgrowth and additional material on the short arm of one of the chromosome 15 in 12% of lymphocytes and 50% of amniotic cells. Parents' karyotypes were normal, indicating a de novo origin for this unbalanced rearrangement. Complementary studies using cytogenetic and FISH studies showed that this additional material resulted in a 15q25-qter trisomy and confirmed the presence of three copies of the insulin-like growth factor 1 receptor (IGF1R) gene, included in the trisomic region. Autopsy performed after termination of pregnancy revealed isolated overgrowth and absence of visceral malformations. The possible mechanisms and origins for the formation of this mosaic pure trisomy are complex. The present observation emphasises the hypothesis that the overgrowth phenotype, frequently reported in patients with trisomy including the 15q26 region, might be causally related to a dosage effect of the IGF1R gene, as well as the importance of chromosome analysis in patients with overgrowth. It also confirms that the overgrowth is of prenatal onset in those observations.
Collapse
Affiliation(s)
- Laurence Faivre
- Centre de Génétique Médicale, Hôpital d'Enfants, Dijon, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Khau Van Kien P, Wolf JE, Mathieu F, Zhu L, Salve N, Lalande A, Bonnet C, Lesca G, Plauchu H, Dellinger A, Nivelon-Chevallier A, Brunotte F, Jeunemaitre X. Familial thoracic aortic aneurysm/dissection with patent ductus arteriosus: genetic arguments for a particular pathophysiological entity. Eur J Hum Genet 2004; 12:173-80. [PMID: 14722581 DOI: 10.1038/sj.ejhg.5201119] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Thoracic aortic aneurysm and aortic dissection (TAA and AD) are an important cause of sudden death. Familial cases could account for 20% of all cases. A genetic heterogeneity with two identified genes (FBN1 and COL3A1) and three loci (3p24-25 or MFS2/TAAD2, 5q13-q14 and 11q23.2-24) has been shown previously. Study of a single family composed of 179 members with an abnormally high occurrence of TAA/AD disease. A total of 40 subjects from three generations were investigated. In addition to five cases of stroke and three cases of sudden death, there were four cases of AD and four cases of TAA in adults. In all, 11 cases of patent ductus arteriosus (PDA) were observed, two of which were associated with TAA and one with AD. Segregation analysis showed that the distribution of these vascular abnormalities was more likely compatible with a single genetic defect with an autosomal dominant pattern of inheritance. There were no clinical signs of Marfan, Elhers-Danlos vascular type or Char syndromes. Genetic linkage analysis was performed for seven genes or loci implicated in familial TAA/AD disease (COL3A1, FBN1, 3p24-25 or MFS2/TAAD2, 5q13-q14 and 11q23.2-q24), Char syndrome (TFAP2B) or autosomal recessive PDA (12q24). Using different genetic models, linkage with these seven loci was excluded. Familial TAA/AD with PDA is likely to be a particular heritable vascular disorder, with an as yet undiscovered Mendelian genetic basis.
Collapse
Affiliation(s)
- Philippe Khau Van Kien
- INSERM U36, Collège de France, and Département de Génétique, Hôpital Européen Georges Pompidou, Paris, France.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Thauvin-Robinet C, Faivre L, Cusin V, Khau Van Kien P, Callier P, Parker KL, Fellous M, Borgnon J, Gounot E, Huet F, Sapin E, Mugneret F. Cloacal exstrophy in an infant with 9q34.1-qter deletion resulting from a de novo unbalanced translocation between chromosome 9q and Yq. ACTA ACUST UNITED AC 2004; 126A:303-7. [PMID: 15054847 DOI: 10.1002/ajmg.a.20596] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Cloacal exstrophy is a rare malformation, belonging to a spectrum of birth defects, which, in order of severity, includes phallic separation with epispadias, pubic diastasis, bladder exstrophy, and cloacal exstrophy. This malformation overlaps the OEIS complex (O = omphalocele, E = bladder exstrophy, I = imperforate anus, S = spinal defects). The etiology of cloacal exstrophy is unknown to date. It may result from either a single defect of early blastogenesis or a defect of mesodermal migration during the primitive streak period. We report an infant with cloacal exstrophy, exomphalos, right kidney agenesis, ambiguous external genitalia, and axial hypotonia. The karyotype showed a de novo unbalanced translocation between the long arm of chromosome 9 and the long arm of chromosome Y resulting in a 9q34.1-qter deletion. Reviewing the literature, we did not find any observation of cloacal exstrophy associated with a structural chromosomal abnormality. The steroidogenic factor 1 (SF1) gene, included in the deleted region, was a good candidate gene but no pathogenic mutation was found by direct sequencing. We hypothesize that another gene, expressed early in embryogenesis and responsible for cloacal exstrophy, is present in the 9q34.1-qter region.
Collapse
|
42
|
Gimenez-Roqueplo AP, Favier J, Rustin P, Rieubland C, Crespin M, Nau V, Khau Van Kien P, Corvol P, Plouin PF, Jeunemaitre X. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res 2003; 63:5615-21. [PMID: 14500403] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/27/2023]
Abstract
Germ-line mutations in the genes encoding succinate dehydrogenase complex subunits B (SDHB) and D (SDHD) have been reported in familial paragangliomas and apparently sporadic phaeochromocytomas (ASP), but the genotype-phenotype relationships of these mutations are unknown. Eighty-four patients (all but 2 followed up for 8.8 +/- 5.7 years) with ASP (57 with adrenal tumors, 27 with extra-adrenal, multiple, malignant, or recurrent tumors) were screened for the major susceptibility genes for phaeochromocytoma (RET, VHL, SDHD, and SDHB). Thirty-three tumors were available for molecular analysis, enzyme assays, and immunohistochemistry. No (0%) RET and 2 (2.4%) VHL mutations were detected. Only two coding single nucleotide polymorphisms in the SDHD gene (G12S and H50R) were found in 6 patients (7%). Conversely, six deleterious mutations in the SDHB gene were identified in 8 patients (9.5%). Ectopic site and recurrence or malignancy were strongly associated with SDHB mutations (7 of 8, 87%, versus 20 of 76, 26%; P = 0.001). Somatic DNA analysis indicated a loss of heterozygosity at chromosome 1p36 (SDHB locus) in 16 of 33 cases (48%). A loss of heterozygosity at the SDHB locus was found in all tumors with SDHB mutation, and assays of respiratory chain enzymes showed a complete loss of complex II catalytic activity. The vascular architecture of tumors with SDHB mutations displayed features typical of malignancy. These data strongly suggest that SDHB gene is a tumor suppressor gene and that the identification of germ-line mutations in SDHB gene in patients with ASPs should be considered as a high-risk factor for malignancy or recurrence.
Collapse
|
43
|
Van Kien PK, Lalande A, Bonnet C, Dellinger A, Petit A, Nivelon-Chevallier A, Brunotte F, Jeunemaitre X, Wolf JE. Familial aortic dissection/aneurysm associated with patent ductus arteriosus: a new entity? J Am Coll Cardiol 2002. [DOI: 10.1016/s0735-1097(02)81186-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|